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ABSTRACT 
This dissertation seeks to provide evidence for interventions that large health systems can 
utilize to help mitigate the prescription opioid epidemic in Pennsylvania.  
Chapter one introduces the research problem  
Chapter two examines the potential for machine-learning approaches to better understand 
the heterogeneity of opioid use in Medicare. What constitutes potentially high-risk use of 
prescription opioids in Medicare is not clearly known. Using novel techniques of machine-
learning, we identify five groups of Medicare beneficiaries with potentially high-risk opioid use 
patterns. We observe that these groups differ not only on measures of opioid use but also on 
important demographic characteristics, clinical characteristics and mortality.  
Chapter three examines the associations between physician prescribing specialties and 
opioid-related outcomes of opioid-use disorder (OUD), misuse, and overdose. Little is known 
about the variations in risk of OUD, misuse, and overdose by type of opioid prescribing specialties. 
Using data from Pennsylvania Medicaid, we examine the associations between the index and 
dominant opioid prescribing specialty and OUD, misuse, and overdose. We observe that Medicaid 
enrollees who receive their index opioid prescription or a majority of their prescriptions from 
specialties that treat chronic pain -pain medicine and physical medicine and rehabilitation- are at 
higher risk for OUD and misuse compared to primary care.  
Julie M. Donohue, PhD 
 
 
PRESCRIPTION OPIOID EPIDEMIC IN PENNSYLVANIA: LESSONS FROM 
MEDICARE AND MEDICAID 
 
Carroline P. Lobo, PhD 
University of Pittsburgh, 2017
 
  v 
 Chapter four examines the associations between adherence to antidepressant medications 
among individuals with mood disorders and opioid use. Literature shows that antidepressants have 
anti-nociceptive effects in mitigating pain among individuals with mood disorders. Using 
Pennsylvania Medicaid data, we examine whether adherence to antidepressants among individuals 
with major depressive disorders (MDD) or anxiety disorders is associated with reduced opioid use. 
We observe that enrollees with MDD and no cancer, who achieve ≥ 20% adherence have 
significantly lower hazards ratios for opioid use than those who achieve <20% adherence. 
This dissertation has important implications for public health. Our findings provide 
evidence for interventions that health-systems can use to: (i) identify high-risk beneficiaries who 
use opioids, (ii) support evidence-based prescribing in settings where patients are at an elevated 
risk for adverse outcomes of opioid use, and (iii) increase adherence to antidepressant medications 
among individuals with MDD. 
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1 CHAPTER ONE: INTRODUCTION 
The United States has seen an increase in drug overdose deaths from 2000 to 2014, with 
nearly half a million individuals dying due to drug overdoses.1 Of the 28,647 prescription drug 
overdose deaths in 2014, 61% were due to opioids.2 Pennsylvania (PA) is one of the main states 
impacted by this epidemic. PA ranked 9th among states in the number of age-adjusted drug 
overdose deaths per 100,000 people from 2011-2013.3  
With the goal of providing evidence-based approaches to inform implementation of 
policies and help mitigate the prescription opioid epidemic in PA, this dissertation uses data from 
two large-health systems - PA Medicare and Medicaid. These health systems are ideal for studying 
utilization of prescription opioids. Medicare and Medicaid provide health care for nearly a third of 
the state’s populations, but likely account for a larger share of the state’s users of prescription 
opioids. For example, for every 100 persons in 2012, physicians in PA prescribed 88.9 opioid 
prescriptions,4 a rate 8% higher than the national average.4 In 2012, 1/3rd of Medicare enrollees 
used opioids for non-cancer pain.5 Further, PA ranked in the top 10 states on providers who wrote 
>3,000 prescriptions for Schedule II controlled substances in Medicare Part D in 2012.6 Past 
studies have shown that opioid utilization for treating chronic non-cancer pain in Medicaid 
nationally is twice as high as compared to commercially insured population.7 From 2007 to 2012, 
long-term opioid use in the PA Medicaid increased from 13.9% to 16.8%8 and the prevalence of 
opioid use disorder (OUD) increased by 56% from 2007 to 2011.8 These data contain valuable 
 2 
information on opioid utilization and offer an ideal opportunity to study important policy-relevant 
questions . This dissertation is composed of three manuscripts. A broad overview of the three 
chapters is provided in the following paragraphs.  
Chapter two (manuscript one) examines the potential for machine-learning approaches to 
better understand the heterogeneity of opioid use in Medicare Part D. High-risk use of opioid 
medications in Medicare has been on the rise. The 2016 Comprehensive Addiction and Recovery 
Act has authorized a “lock-in” program to limit high-risk use of opioid medications by restricting 
the number of opioid prescribers/pharmacies for some beneficiaries.9 What constitutes “high-risk 
use” of prescription opioids among the elderly or disabled Medicare beneficiaries is subject to 
debate. Further, little is known about the characteristics of those with high-risk use of opioid 
medications. In this chapter, we advance the science of identifying sub-groups of Medicare 
beneficiaries with “high-risk” opioid use patterns using novel unsupervised machine-learning 
techniques. These techniques handle complex interactions among variables of interest. We identify 
five distinct groups that differ not only on measures of opioid use, but also on demographic and 
clinical characteristics, and mortality. We also observe that dual and disabled beneficiaries obtain 
prescriptions from far more prescribers and pharmacies than the non-dual, non-disabled elderly. 
Chapter three (manuscript two) examines the associations between physician prescribing 
specialties and opioid-related outcomes of OUD, misuse, and overdose. Opioids are prescribed for 
acute and chronic pain by numerous specialties for both short and long-term pain. However, there 
is little information on the variations in risk of OUD, misuse, and overdose by type of opioid 
prescribing specialties. Using data from PA Medicaid (2007-2015), we examine the associations 
between the index and dominant opioid prescribing specialty and OUD, misuse, and overdose. We 
report differences in rate of adverse events associated with opioid use based on the provider 
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specialties from whom opioid-naive Medicaid enrollees obtain their first prescription, and a 
majority of their prescriptions. Our results show that Medicaid enrollees who receive their index 
opioid prescription or a majority of their prescriptions from specialties that treat chronic pain -pain 
medicine and physical medicine and rehabilitation- are at higher risk for OUD and misuse than 
those who receive their index prescriptions or a majority of their prescriptions from primary care. 
The differences in adverse events may arise from the clinical needs of patients seeking care from 
certain specialties, from the prescribing behaviors of particular specialties or a combination of both 
these factors.  
 Chapter four (manuscript three) examines the associations between adherence to 
antidepressant medications among individuals with mood disorders and opioid use. Individuals 
with psychiatric illnesses are not only highly likely to receive opioid medications, but are also at 
highest risk for adverse consequences of opioid use such as abuse, misuse, and overdose.10-13 
Literature shows that antidepressants have anti-nociceptive effects in mitigating pain among 
individuals with mood disorders.14,15 We conduct a longitudinal retrospective study using PA 
Medicaid data (2007-2015) to examine the associations between adherence to antidepressants and 
time to the first use of opioid medications. We measure adherence using proportion of days with 
antidepressant medication during a 180-day period. We observed that enrollees with major 
depressive disorders and no cancer who achieve ≥ 20% adherence have lower hazards ratios for 
opioid use compared to those who achieve <20% adherence. The implications of our findings will 
be discussed in detail in the respective chapters. 
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2 CHAPTER TWO: USING UNSUPERVISED MACHINE LEARNING TO IDENTIFY 
HIGH-RISK OPIOID USE IN MEDICARE 
ABSTRACT 
Background: In an effort to address rising opioid overdose deaths, payers including Medicare are 
implementing surveillance programs to identify high-risk opioid use. Most algorithms for 
identifying individuals at risk are based on some combination of information on opioid dose, 
duration of use, and number of unique opioid prescribers and pharmacies. Unfortunately, these 
algorithms are often based on arbitrary thresholds and seldom account for potentially complex 
interactions among these variables. We explored the potential for machine-learning approaches to 
identify groups of Medicare enrollees based on several measures of opioid use, and examined 
differences in clinical characteristics and mortality rates.  
Methods: We included all fee-for-service beneficiaries enrolled in Medicare Part D in 
Pennsylvania who initiated new episodes of prescription opioid use (n= 186,799) after excluding 
beneficiaries with metastatic cancer, long-term care or hospice use. We used the mean, maximum, 
and range of three variables to examine opioid use: morphine milligram equivalents (MME)/ day, 
number of unique opioid prescribers, and number of unique pharmacies. We used k-means 
clustering to jointly assess the clustering variables. We compared demographic, enrollment, 
clinical (e.g. pain diagnoses), and other medication use (e.g. antidepressants) characteristics using 
chi-square and Kruskal Wallis tests. We also compared hazard ratios for all-cause mortality among 
groups using cox proportional hazards regression.   
Results: Using optimal cluster selection criteria, we identified five groups and reported the mean 
of the maximum values across all episodes per beneficiary on variables of interest. The largest 
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group making up 70.9% of the sample (n=132,469) filled opioid prescriptions from a mean 
maximum of 1.3 [standard deviation (SD)= 0.5] prescribers, from 1.0 (SD= 0.2) pharmacy and had 
a mean maximum MME/day of 44.7 (SD= 37.6). By contrast, the highest use group was small 
(n=1,192, 0.6%) and filled opioid prescriptions from a mean maximum of 9.1 (SD= 4.4) 
prescribers and 6.0 (SD=2.4) pharmacies with 125.1 (SD=113.7) MME/day. Hazard ratios for 
mortality for beneficiaries in the highest use sub-group had was 1.56, 95% Confidence Interval 
=1.27, 1.93 relative to the lowest use group. 
Conclusion: The cluster categorization observed in this study can support risk stratification for 
surveillance based interventions such as prescription-drug monitoring and lock-in programs.  
KEYWORDS: Opioids, Medicare, Machine-learning, Prescribers, Pharmacies, Morphine 
Equivalents 
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2.1 INTRODUCTION 
Medicare Part D spending on commonly abused prescription opioids (e.g. oxycodone, 
hydrocodone-acetaminophen) reached $4.1 billion in 2015 representing an increase of 165% since 
its inception in 2006.16 With this widespread use, concerns have been raised about opioid abuse, 
misuse, and diversion among Medicare beneficiaries. The Centers for Medicare and Medicaid 
Services (CMS) have taken several steps in addressing the opioid epidemic in Medicare. For 
example, in 2013 CMS adopted the Overutilization Monitoring System (OMS) requiring plan 
sponsors to enhance their use of monitoring tools such as quantity limits and drug utilization 
reviews.17 The Medicare Advantage Prescription System (MARx) implemented in 2014 enables 
monitoring of point-of-sale of prescription opioids and allowing plan sponsors to identify aberrant 
users.18 The  Comprehensive Addiction and Recovery Act-2016 authorizes Medicare to implement 
a recipient restriction (lock-in) program.9 Lock-in programs, whereby select enrollees who overuse 
prescription opioids are restricted to a designated prescriber and/or pharmacy, have been adopted 
by most state Medicaid programs although the criteria used to determine eligibility vary widely 
across all states.19 
There are important challenges to implementation of these surveillance efforts in Medicare. 
First, there is a lack of consensus on what constitutes overutilization.19-21 Algorithms to identify 
overuse or high-risk opioid use often rely on some combination of information on the number of 
opioid prescribers, number of pharmacies where opioid prescriptions are filled, and/or dose and 
duration of use. For example, in some cases, a threshold of obtaining opioid prescriptions from ≥5 
unique providers is considered as doctor shopping in Medicare.22 Recently, CMS used a threshold 
of > 120 morphine milligram equivalents (MME)/day over 90 days and obtaining opioid 
prescriptions from > 3 prescribers and filling prescriptions at > 3 pharmacies during a 12-month 
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period to measure potential overuse.23,24 The criteria to measure MME/day were based on an 
initiative in Washington State.23,25 These definitions do not take into account the possible 
interaction between these variables. For example, an enrollee may fill high-dose prescriptions from 
one provider or pharmacy but may not qualify for surveillance-based interventions using only the 
number of prescribers and pharmacy criteria given above. A second challenge for Medicare is that 
most of the prior studies identifying risk factors for prescription opioid use are based on data from 
Medicaid and commercially insured populations26-32, the findings of which may not apply to 
Medicare which is limited to elderly and disabled enrollees.  
In this paper, we attempted to advance the science of identifying high-risk sub-groups of 
Medicare beneficiaries filling opioid prescriptions by applying machine-learning approaches. We 
used a technique of unsupervised machine learning which uses partitional clustering algorithms 
(k-means) to group large datasets into meaningful sub-groups. Rather than applying arbitrary 
thresholds, the k-means procedure allowed identification of sub-groups based on the distribution 
of observations across the clustering variables. Although we used the same variables as used by 
the above-mentioned surveillance programs, there are two important differences to our approach. 
First, we used more information (mean, maximum and range) on the variables of interest over six-
month episodes per beneficiary rather than applying pre-determined thresholds. Second, the k-
means clustering technique accounted for potential interactions between these variables. The 
groups were therefore based on a joint assessment of all clustering variables measuring opioid use. 
Given the little information available on the extent of heterogeneity of opioid use in Medicare, this 
procedure provided an ideal opportunity to investigate our study objective. 
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2.2 METHODS 
2.2.1 Data Source 
We conducted a longitudinal analysis using 2007-2012 data on all fee-for-service 
Pennsylvania Medicare enrollees with a Part D plan. Pennsylvania is the 5th largest state in terms 
of total Medicare beneficiaries33, with high rates of opioid utilization.4,11,34 We used enrollment 
files to obtain beneficiary demographic characteristics (e.g. age, race, sex), reason for eligibility 
(e.g. disabled vs. aged) and presence of low-income subsidy for the Part D benefit, and enrollment 
duration. We used the inpatient (MEDPAR), outpatient, carrier claims, and home health files to 
obtain information on beneficiary diagnosis and procedure codes. The Prescription Drug Event 
(PDE) file included prescription characteristics such as the National Drug Code (NDC), days’ 
supply, date of fill, and dose. We used the Medispan® database to obtain other information on 
prescription characteristics such as drug name, strength, and active ingredient by NDC.35 We used 
the unique provider identifiers (IDs) from the PDE files to identify unique prescribers and 
pharmacies for this study. Less than 1% of opioid claims had missing IDs for both prescribers and 
pharmacies. 
2.2.2 Study sample  
Our analytic cohort included adult fee-for-service, elderly and disabled Medicare enrollees 
residing in Pennsylvania, with Part D coverage and included enrollees dually eligible for Medicaid. 
We did not include Medicare Advantage participants as we did not have complete information on 
their medical claims needed for constructing covariates. We excluded the following group of 
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enrollees who are likely to have different opioid use patterns – i) those with any metastatic cancer 
diagnosis identified using International Classification of Diseases, 9th version, Clinical 
Modification (ICD-9-CM)36, ii) those residing in long-term care facilities or those obtaining their 
opioid prescriptions from long-term care pharmacies (using the primary pharmacy type variable 
in the PDE file), and iii) those receiving hospice services (using place of service codes).  
2.2.3 Cohort design and unit of observation 
The unit of analysis was the person-level, however, the unit of observation was opioid use 
episodes observed during the study period for each beneficiary. An episode began with the first 
prescription of oral, transdermal, or submucosal opioid medication (index event) and ended if there 
was a gap of six months or more between two consecutive opioid prescriptions (Figure A.1).37 
The index event was preceded by a baseline observation period, in which we required patients to 
have continuous six-months of enrollment and no opioid prescription fills. Episodes varied in 
length and each patient could have multiple episodes. Within each episode, we created measures 
of opioid utilization described in detail below over six-month episodes (Figure A.2). We then 
created aggregated measures of opioid use across each beneficiaries’ episodes (described below). 
Most PDMP and lock-in programs identify opioid utilization using specific thresholds for number 
of opioid prescribers, pharmacies or MME observed over varying time intervals. We used a six-
month interval over which we observed specific opioid fill patterns to allow for sufficiently long 
follow-up time.23,38 
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2.2.4 Unsupervised k-means analysis  
Clustering is a classification technique that groups observations in a dataset such that 
observations within a group are as similar as possible on the clustering variable of interest than 
observations in other groups. We used an unsupervised clustering technique to identify sub-groups 
of enrollees using opioids primarily due to CMS’ policy at the time that claims with diagnoses of 
substance use disorders would be redacted.39,40 This policy prevented us from creating relevant 
outcome variables necessary for supervised machine learning algorithms, such as hospitalizations 
for overdose.  
Several unsupervised clustering methods exists and can be classified as partitional, 
hierarchical, density-based, and grid-based clustering.41 We used the partitional clustering 
technique known as k-means due to its ability to handle our large sample size. The k-means 
technique works by: i) choosing k random points as initial cluster centers, ii) assigning and re-
assigning observations to cluster centers till the distance between each observations in a cluster 
and the cluster centroid reaches a minimum.42 The choice of ‘k’ clusters depends on the a priori 
relationships. Since we did not have any a priori assumptions, we varied ‘k’ from two to 10 clusters 
using the ‘clusterR’ package in R.43,44 The optimal number of clusters was chosen using the 
following indices: Akaike Information Criteria (AIC), Bayesian Information Criteria (BIC), and 
sum of the within-cluster-sum-of-squares-of-all-clusters (WCSSE). We compared the ratio of 
change for each of these indices across all values of the clusters. Since the values of each of these 
indices may improve with increasing the number of clusters, we chose the optimal cluster number 
as the one corresponding to the first highest ratio of change (Table A.1).  
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2.2.5 Clustering variables 
We relied on opioid utilization measures often used by payers to identify patients at risk of 
overdose or other adverse opioid related outcomes. The key difference was that we did not impose 
arbitrary cut points for the variables of interest but rather used k-means to identify distinct clusters 
based joint assessment of the measures of interest. First, we identified the number of unique opioid 
prescribers identified in Medicare PDE files during each six-month episode. Second, we identified 
the number of unique opioid pharmacies associated with a pharmacy claim during the same six-
month episode. Third, we included the standardized MME45 measure that captured the quantity, 
strength, and the morphine conversion factor. The MME/day was calculated by dividing the total 
MME by the duration of days supplied. To capture complete information on opioid use across all 
six-month episodes and to capture variability within individuals, we used the mean, maximum, 
and range of the above variables each measured over six-month periods across all episodes per 
beneficiary. For example, for a beneficiary with two episodes, with values of 50 MME/day and 
120 for MME/day, we would choose 120 as the maximum value, 85 as the mean, and 70 (120-50) 
as the range for clustering purposes. This approach yielded a total of nine opioid use measures for 
each individual in the sample (mean, maximum, and range for each of the three outcomes: MME, 
number of prescribers and number of pharmacies).  
2.2.6 Characteristics of clusters 
After identifying the sub-groups (clusters) we compared their characteristics including: 1) 
demographic and enrollment, 2) clinical diagnoses, and 3) use of other medications. Demographic 
variables were measured at baseline and included: age at first episode, gender, race/ethnicity, and 
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place of residence (urban/rural). Enrollment variables included an indicator for Medicare 
eligibility due to disability, dual-eligibility for Medicaid and receiving low-income subsidy (LIS). 
For the clinical diagnoses, we compared the sub-groups for presence of at least one ICD-9-CM 
claim for the following conditions at any point during the six-year observation period with a focus 
on mental disorders and pain conditions based on prior studies showing these diagnoses to be 
associated with opioid use46: i) adjustment disorders, ii) anxiety disorders, iii) mood disorders, iv) 
personality disorders, v) other mental health disorders, vi) back pain, vii) neck pain, viii) 
arthritis/joint pain, ix) headache/migraine, and x) HIV/AIDS. Also, given the high rates of use of 
other medications with opioids as reported by prior studies47, we compared use of the following 
drug classes: i) antidepressants, ii) anticonvulsants, iii) antipsychotics, iv) muscle relaxants, and 
v) stimulants. Use of other medications was defined as use of drugs from the aforementioned 
therapeutic classes during the same six-month episodes as opioid use. 
2.2.7 All-cause mortality 
Since we did not have overdose or opioid-use disorder related outcomes due to CMS 
redaction, we compared all-cause mortality among the groups. All-cause mortality was identified 
using the date of death variable.  
2.2.8 Statistical analyses 
Since the maximum values of the three clustering variables are most likely to be identified 
by surveillance activities conducted by prescription drug- monitoring programs, lock-in programs 
and other monitoring activities, in the results section we report the maximum values for a given 
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variable for beneficiaries in each cluster.  To compare differences in the groups across all clustering 
variables, we performed Kruskal-Wallis tests. To compare differences in the groups across non-
clustering variables, we performed Chi-square tests for categorical variables (e.g. gender, race) 
and one-way analysis of variance for continuous variables (e.g. age at first episode). To compare 
all-cause mortality among the groups, we conducted cox proportional hazards regression where 
we controlled for demographic characteristics - age, gender, race (white/ non-white); enrollment 
characteristics - dual eligibility for Medicaid, presence of low-income subsidy, presence of 
disability; and, baseline comorbid conditions including (i) adjustment disorders, ii) anxiety 
disorders, iii) mood disorders, iv) personality disorders, v) other mental health disorders, vi) back 
pain, vii) neck pain, viii) arthritis/joint pain, ix) headache/migraine, and x) HIV/AIDS. Finally, we 
included a modified Elixhauser comorbidity index.48 We used SAS 9.4. for data management and 
other statistical analyses.49 This study was designated as exempt from University of Pittsburgh’s 
Institutional Review Board. 
2.3 RESULTS 
2.3.1 Characteristics of study sample 
There were 895,047 beneficiaries who were enrolled in fee-for-service Medicare and a 
stand-alone Part D plan in Pennsylvania between 2007 and 2012. After applying the inclusion and 
exclusion criteria, we had a final sample size of 186,799 beneficiaries with a total of 310,779 
episodes (Figure A.3). This cohort was predominantly white (87.8%), female (61.4%) and lived 
in urban areas (85.0%). The mean age for this cohort was 64.2 years (standard deviation 
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(SD)=15.7), reflecting the large proportion (37.7%) of under-65 disabled Medicare enrollees in 
our sample (Table 2.1). Approximately 69% enrollees participated in the Part D low-income 
subsidy program. Enrollees had a mean of 1.7 (SD=1.0) and a median of 1 episode (minimum=1, 
maximum= 8).  
Table 2.1 Patient-level cohort characteristics 2007 to 2012 
Total  186,799 
Age, Mean (± SD) 64.2 (15.7) 
Gender, n (%) 
Female               114,623 (61.4) 
Race, n (%) 
White   163,912 (87.8) 
Black   16,088 (8.6) 
Hispanic   2,407 (1.3) 
Other   4,392 (2.3) 
Residence, n (%) 
Urban 158,679 (85.0) 
Disabled, n (%) 70,420 (37.7) 
Dual-eligible, n (%) 100,752 (53.9) 
Low-income subsidy, n (%) 127,927 (68.5) 
Eligible opioid use episodes 
Mean (SD) 1.7 (1.0) 
Median (min-max) 1 (1-8) 
 SD = standard deviation; min=minimum; max=maximum 
 
2.3.2 Characteristics of clustering variables 
We identified five groups based on the cluster selection criteria discussed above (Table 
A.1). We present the maximum values on the clustering variables in this section. The largest group 
with the lowest values on all variables of interest (hereafter ‘low dose, few providers’ group) 
constituted 70.9% (n=132,469) of all beneficiaries (Table 2.2). The maximum number of opioid 
prescribers per beneficiary across all episodes in the low dose, few providers group was, on 
average, 1.3 (SD=0.5) prescribers and the mean maximum number of pharmacies was 1.0 
(SD=0.2). The mean maximum MME/day per beneficiary across episodes was 44.7 (SD=37.6). 
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Beneficiaries in group 2 (hereafter ‘moderate dose, moderate pharmacies, few providers’ group; 
n=36,740; 19.7%) had slightly higher unique prescribers (3.0, SD=0.9), pharmacies (1.7, SD=0.6) 
and MME/day (62.2, SD=53.1) compared to the low dose, few providers group. Similarly, 
beneficiaries in group 3 (hereafter ‘moderate dose, moderate providers’ group; n=10,503; 5.6%) 
had slightly higher unique prescribers (4.4, SD=1.6), pharmacies (3.2, SD=0.9) and MME/day 
(97.3, SD=101.6) compared to the low dose, few providers or moderate dose, moderate 
pharmacies, few providers groups. Group 4 (hereafter ‘high dose, few providers’ group; n=5,895; 
3.2%) had the highest mean maximum MME/day of 168 (SD=158.5) compared to the other four 
groups. However, this group obtained prescriptions from a maximum of 2.0 (SD=0.9) unique 
prescribers and 1.3 (SD= 0.6) unique pharmacies over a six-month period. Group 5 (hereafter ‘high 
dose, multiple providers’ group) was small (n=1,192; 0.6%), but had a markedly higher number 
of unique prescribers (9.1, SD=4.4) and pharmacies (6.0, SD=2.4) compared to other groups. The 
MME/day for the high dose, multiple providers was 125.1 (SD= 113.7). 
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Table 2.2 Characteristics of the groups based on clustering variables 
Total beneficiaries 
N=186,799 
 
Low 
dose, few 
providers 
n=132,469 
(70.9%) 
Moderate 
dose, moderate 
pharmacies, few 
providers 
n=36,740 
(19.7%) 
Moderate 
dose, moderate  
providers  
n=10,503 
(5.6%) 
High 
dose, few 
providers 
n=5,895 
(3.2%) 
High  
dose, 
multiple 
providers 
            
n=1,192 
       (0.6%) 
P 
Maximum values of clustering variables 
Morphine Milligram 
Equivalents per day, 
mean (SD) 
44.7 
(37.6) 
62.2 
(53.1) 
97.3 
(101.6) 
168 
(158.5) 
125.1 
(113.7) 
<0.0001 
Number of unique 
prescribers, mean, 
(SD) 
1.3 
(0.5) 
3.0 
(0.9) 
4.4 
(1.6) 
2.0 
(0.9) 
9.1 
(4.4) 
<0.0001 
Number of unique 
pharmacies, mean 
(SD) 
1.0 
(0.2) 
1.7 
(0.6) 
3.2 
(0.9) 
1.3 
(0.6) 
6.0 
(2.4) 
<0.0001 
Mean of clustering variables 
Morphine Milligram 
Equivalents per day, 
mean (SD) 
39.1 
(32.6) 
43.5 
(38.9) 
63.5 
(67.5) 
99.8 
(116.0) 
76.3 
(47.9) 
<0.0001 
Number of unique 
prescribers, mean 
(SD) 
1.2 
(0.4) 
1.9 
(0.7) 
2.4 
(0.9) 
1.4 
(0.4) 
4.4 
(2.2) 
<0.0001 
Number of unique 
pharmacies, mean 
(SD) 
1.0 
(0.2) 
1.3 
(0.4) 
1.9 
(0.6) 
1.1 
(0.2) 
3.1 
(1.2) 
<0.0001 
Range of clustering variables 
Morphine Milligram 
Equivalents per day, 
mean (SD) 
10.4 
(24.1) 
33.9  
(40.0) 
60.9 
(78.2) 
120.9 
(118.9) 
88.4 
(92.0) 
<0.0001 
Number of unique 
prescribers, mean 
(SD) 
0.2 
(0.4) 
1.7 
(1.0) 
3.2 
(1.6) 
1.0 
(0.9) 
7.7 
(4.3) 
<0.0001 
Number of unique 
pharmacies, mean 
(SD) 
0.0 
(0.1) 
0.6 
(0.5) 
2.1 
(0.9) 
0.3 
(0.6) 
4.7 
(2.3) 
<0.0001 
SD= standard deviation; The values represent the mean of the maximum/mean/range across all six-month episodes. The Kruskal Wallis 
statistical tests were performed to compare differences in the clustering variables across sub-groups. 
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2.3.3 Demographic and enrollment characteristics by groups 
Compared to the other groups, beneficiaries in the low dose, few providers group had an 
average age of 66.5 years (SD=15.0) (Table 2.3) with the fewest disabled (30.2%) beneficiaries. 
By contrast, beneficiaries in the high dose, multiple providers group were the youngest (42.7, 
SD=10.8 years) and had the highest proportion of disabled (97.6%) and dual-eligible (90.6%) 
beneficiaries compared to the other groups. The high dose, few providers group that had the highest 
mean maximum MME/day had a mean age of 63.8 (SD=15.8) years with 38.7% disabled and 
49.4% dual-eligible beneficiaries. 
Table 2.3 Demographic and enrollment characteristics of the groups 
Total 
beneficiaries 
N=186,799 
 
Low dose, few 
providers 
=132,469 
(70.9%) 
Moderate 
dose/moderate 
pharmacies/few 
providers 
n=36,740 
(19.7%) 
Moderate 
dose/moderate 
providers  
n=10,503 
(5.6%) 
High-dose, few 
providers 
n=5,895 
(3.2%) 
High dose, 
multiple 
providers 
n=1,192 
(0.6%) 
P 
Age at first episode, 
mean (SD) 
66.5 
(15.0) 
60.5 
(15.7) 
51.0 
(14.5) 
63.8 
(15.8) 
42.7 
(10.8) 
<0.0001 
Female, n (%) 80,837 
(61.0) 
23,099 
(62.9) 
6,044 
(57.6) 
4,031 
(68.4) 
612 
(51.3) 
<0.0001 
White, n (%) 116,873 
(88.2) 
32,012  
(87.1) 
8,665 
(82.5) 
5,407 
(91.7) 
955 
(80.1) 
<0.0001 
Disabled, n (%) 40,004 
(30.2) 
18,736 
(51.0) 
8,241 
(78.5) 
2,284 
(38.7) 
1,155 
(96.9) 
<0.0001 
Dual eligible, n (%) 66,576 
(50.3) 
22,126 
(60.2) 
8,057 
(76.7) 
2,912 
(49.4) 
1,081 
(90.6) 
<0.0001 
LIS, n (%) 87,054 
(65.7) 
27,083 
(73.7) 
9,049 
(86.2) 
3,578 
(60.7) 
1,163 
(97.6) 
<0.0001 
Urban living area, n 
(%) 
112,998 
(85.3) 
30,768 
(83.8) 
9,019 
(85.9) 
4,823 
(81.8) 
1,071 
(89.9) 
<0.0001 
LIS=Low-income subsidy, SD= Standard Deviation; One-way analysis of variance was performed to compare differences across groups 
for continuous variables and chi-square tests for categorical variables. 
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2.3.4 Use of other medications use by groups  
Use of other medications is represented in Figure 2.1 via a spider-diagram which shows 
the mean maximum number of prescription fills for all groups based on the following therapeutic 
classes: 1) antipsychotics, 2) antidepressants, 3) anticonvulsants, 4) muscle relaxants, and 5) 
stimulants. The two groups with the highest use of both psychiatric medications and muscle 
relaxants were the high dose, multiple providers and moderate dose, moderate providers groups. 
The mean maximum number of fills for the high dose, multiple providers group were: 3.2 (SD=4.7) 
for antipsychotics, 6.3 (SD=5.4) for antidepressants, 4.0 (SD=4.6) for anticonvulsants, and 3.8 
(SD=3.8) for muscle-relaxants. The moderate dose, moderate providers group has slightly lower 
use of other medications than the high dose, multiple providers group, yet filled comparatively 
more prescriptions than the remaining three groups as follows: 1.8 (SD=3.9) for antipsychotics, 
4.7 (SD=5.0) for antidepressants, 2.9 (SD=3.9) for anticonvulsants, and 2.2 (SD=3.0) for muscle-
relaxants. The ranges of other medication use for the remaining groups were as follows: 1) 
antipsychotics, 0.4 (SD=2.0) to 0.9 (SD=2.8), 2) antidepressants, 1.2 (SD=2.7) to 3.1 (SD=4.2); 3) 
anticonvulsants, 0.6 (SD=2.0) to 1.8 (SD=3.2), 4) muscle relaxants, 0.3 (SD=0.9) to 1.1 (SD=2.1). 
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2.3.5 Presence of comorbid conditions by groups 
 We found that the high dose, multiple providers group had the highest prevalence of mental 
health conditions as follows (Table 2.4): any mental illness (91.4%), anxiety disorders (76.5%), 
mood disorders (83.4%), adjustment disorders (17.6%), other mental health disorders (30.5%). 
Similarly, we also found the highest prevalence of physical health conditions in the high dose, 
multiple providers group as follows: any chronic pain (99.2%), back pain (94.9%), neck pain (73.8 
%), arthritis/joint pain (97.1%), and headache/migraine (38.0%). Across the remaining three 
groups, the prevalence of any mental illness was ranging from 43% to 78.5%, and prevalence of 
any chronic pain was from 87.7% to 98.1 %. 
Note: This figure represents the distribution of the mean of the maximum values of prescriptions fills for 
antipsychotics, antidepressants, anticonvulsants, stimulants, and muscle relaxants across the five groups. There were 
significant differences in the maximum prescription fills across the five subgroups as observed by Kruskal Wallis 
tests. Group 1= Low dose, few providers; Group 2= Moderate dose, moderate pharmacies, few providers; Group 3= 
Moderate dose, moderate providers; Group 4= High dose, few providers; Group 5= High dose, multiple providers 
 
  
 
Figure 2.1 Spider diagram representing use of other medications by groups 
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Table 2.4 Comorbid conditions among clusters at any given time during the observation period (2007-2012) 
Total  
beneficiaries 
N=186,799 
 
Low dose/few 
providers =132,469 
(70.9%) 
Moderate 
dose/moderate 
pharmacies/few 
providers 
n=36,740 
(19.7%) 
Moderate 
dose/moderate 
providers  
n=10,503 
(5.6%) 
High-dose, 
few providers 
n=5,895 
(3.2%) 
High dose, multiple 
providers 
n=1,192 
(0.6%) 
Any mental health 43.0 62.8 78.5 58.4 91.4 
Adjustment disorders 4.3 7.4 11.7 7.2 17.6 
Anxiety disorders 25.9 40.7 56.2 38.5 76.5 
Mood disorders 29.2 48.6 66.6 42.8 83.4 
Psychotic disorders 6.8 9.4 14.6  7.9 23.9 
Other mental health disorders 6.5 11.8 19.0 11.3 30.5 
Any chronic pain 87.7 96.2 98.1 97.4 99.2 
Back pain 57.0 79.1 88.3 79.9 94.9 
Neck pain 28.9 45.1 59.4 47.2 73.8 
Arthritis/joint pain 81.1 91.1 93.4 93.4 97.1 
Headache/migraine pain  6.9 14.0 24.1 13.2 38.0 
HIV/AIDS 0.8 1.4 2.7 0.8 3.7 
Note: The numbers represent column percentages or prevalence of conditions within each group as measured by the presence of at least one ICD9 diagnosis claim (inpatient, outpatient, 
or professional) at any time during the observation period (2007-2012); Chi-square tests were performed to compare differences in prevalence of comorbid conditions across all five 
groups; Any pain refers to the presence of either back, neck pain, arthritis/joint pain, or headache/migraine during the observation period; All differences were significant at the  p=0.001 
level 
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2.3.6 Hazard ratios for of all-cause mortality    
Finally, we investigated the hazard ratios of all-cause mortality associated with specific 
groups. The low dose, few providers group was used as the reference group since this group had 
the least utilization with respect to the clustering variables. We observed that beneficiaries who 
had the highest values on the number of prescribers and pharmacies had the highest hazard ratios 
for all-cause mortality relative to beneficiaries in the low dose, few providers group. Beneficiaries 
in the high dose, multiple providers had 1.56 [95% CI=1.27, 1.93] times higher hazards of all-
cause mortality compared to beneficiaries in the low dose, few providers group (Figure 2.2). 
Beneficiaries in the moderate dose, moderate providers had 1.10 [95% CI=1.01, 1.19] times higher 
odds of all-cause mortality compared to beneficiaries the low dose, few providers group.  
 
 
 
Figure 2.2 Hazard ratios for all-cause mortality associated with each group 
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2.4  DISCUSSION 
 Using techniques of cluster analysis, we examined opioid use patterns across six-month 
periods per beneficiary. Our study found markedly heterogeneous opioid use among Pennsylvania 
Medicare beneficiaries and had three key findings. First, the cluster analysis found five distinct 
groups based on the number of prescribers, pharmacies, and MME/day. There were large 
magnitude of differences in opioid use measures across the five sub-groups. Since the groups were 
based on a joint assessment of all clustering variables, the clustering technique improves on 
existing approaches and yielded groups that may not have been identified using other approaches. 
For example, beneficiaries in the high dose, multiple providers group had the highest values on 
number of prescribers and pharmacies but not on MME/day. Second, the groups with the highest 
values on opioid use measures also significantly differed in use of antipsychotics, antidepressants, 
anticonvulsants, and muscle-relaxants and the prevalence of mental illnesses and pain diagnoses. 
And, third, the group with the highest values on number of prescribers and pharmacies (high dose, 
multiple providers and moderate dose, moderate providers) had the highest hazard ratios for all-
cause mortality compared to the groups with the least values on the three clustering variables of 
interest. 
Rather than using pre-specified thresholds, the k-means technique used in this study offered 
the benefits of identifying potentially high-risk enrollees who use opioids by accounting for 
potential interactions between important variables measuring opioid use. Due to the CMS-initiated 
redaction of substance-abuse claims39,40, we could not measure adverse outcomes of opioid use - 
overdose and opioid-use disorder. Therefore, we could not investigate how risk of overdose or 
opioid-use disorder varies with changes in opioid utilization patterns. Prescription drug monitoring 
programs and lock-in programs typically have access mainly to prescription data on controlled 
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substances. The lock-in programs run by several state Medicaid programs often rely on a 
retrospective review of prescriber, pharmacy, and other opioid prescription characteristics to 
identify beneficiaries eligible for surveillance-based interventions (e.g. restriction opioid 
prescriptions to one-provider).19 In a way, these techniques often rely on “unsupervised” 
approaches like that used this study to identify patients at risk. The technique used in this paper 
improves on existing approaches by shedding light on the interactions between important variables 
used by surveillance programs to measure opioid overuse or abuse when other data such as clinical 
diagnoses are not available.  
Many studies have previously examined characteristics of opioid use such as MME/day 
and doctor/pharmacy shopping among young or middle-aged adults.27-30,50 In this study, we 
examined characteristics of opioid use in a disabled or elderly Medicare population. CMS has 
recently employed a threshold of >120 MME/day over 90 days and/or obtaining opioid 
prescriptions from > 3 prescribers and filling prescriptions at > 3 pharmacies during the same 
period as indicators of over utilization.23 Although we measure MME over the entire six-month 
episode and not 90 days, beneficiaries in the high dose, multiple providers group (0.6% of the 
sample) would meet those criteria. 
Our findings reflect that Medicare beneficiaries who could potentially be classified under 
the high dose, multiple providers category appear to have complex health needs. In our study, 
beneficiaries who obtained prescriptions from multiple providers (high dose, multiple providers 
and moderate dose, moderate providers groups) had higher proportion (over 75%) of disabled and 
dual-eligible (low-income) beneficiaries compared to the other groups. We also observed higher 
prevalence of back pain, neck pain, mood disorders and high use of other medications in these 
groups. For example, beneficiaries in the high dose, multiple providers group had on an average, 
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a maximum of six prescriptions of antidepressants, four prescriptions of muscle-relaxants and four 
prescriptions anticonvulsants during the six months of opioid use. We cannot ascertain whether 
these beneficiaries were intentionally seeking opioid prescriptions from multiple doctors and 
pharmacies or simply seeking treatment for complex health needs from multiple providers with 
unintended consequences for opioid prescribing. Therefore, before implementing policies to 
reduce overutilization of prescription opioids, our findings highlight that it is important to 
recognize that those with potentially high-risk opioid use may have complex healthcare needs. The 
heterogeneity we observed in our study implies that policies having a “one-size fits all” approach 
may not help reduce opioid overuse. Instead of using definitive thresholds, existing surveillance 
efforts can be improved by first ascertaining the health needs of the population.  
Currently, upon identifying overutilization, Part D plan sponsors can conduct 
prescriber/pharmacy and/or patient-specific education and outreach interventions.51 If these efforts 
are not successful, recent legislation allows restriction of opioid use among these beneficiaries.9 
However, little is known about the impact of such restrictions on pain treatment for Medicare 
beneficiaries with complex medical and behavioral health needs. Managing the health needs of 
this population may require delivery system reforms that allow integration of behavioral health 
and treatment of substance use disorders with physical health care models such that continuity of 
care is available for these patients. The Screening, Brief Intervention and Referral to Treatment 
(SBIRT)52,53 model or the Collaborative Opioid Prescribing model54 are examples of integrated 
service delivery systems that may be useful in this context. Our results can be utilized by current 
legislation for designing restriction programs in Medicare.9 Restriction programs have been in 
existence since the late 1970s55, and have shown to be successful in reducing opioid abuse and 
overdose.56 However, these programs have largely been implemented in Medicaid. Given that 
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Medicaid beneficiaries are more likely to be at risk for adverse outcomes of opioid over utilization 
such as overdose than other populations57, the eligibility criteria used by Medicaid to enroll 
patients in restriction programs may not apply to Medicare. Although this study does not identify 
the right thresholds for doctor/pharmacy shopping or MME/day, the results provide some direction 
into the average values on these measures in the Pennsylvania fee-for-service Medicare population.  
Our study has some potential limitations. First, our data cannot identify prescriptions not 
paid for by Medicare. For example, cash payments for prescriptions (e.g. Medicare coverage gap) 
cannot be captured. Second, prescriptions filled by an enrollee are not necessarily consumed by 
that enrollee. However, both these issues are observed in most health care claims since they do not 
capture variables such as blood tests or urine drug screens information that can help validate 
medication consumption. In the absence of substance-abuse claims, we examined differences in 
all-cause mortality among the sub-groups. An important limitation was that cause of death was not 
available. We used the date of death to identify all-cause mortality. Finally, limiting our analyses 
to only Pennsylvania Medicare claims reduces the external validity of our findings. Despite these 
limitations, our study utilized a six-year longitudinal cohort to answer essential and timely policy-
relevant questions.  
2.5 CONCLUSIONS 
The clustering technique used in this study identified five distinct groups that differed not 
only on measures of opioid use, but also differed on demographic, clinical, and other medication 
use characteristics. More importantly we observed that dual and disabled beneficiaries obtained 
prescriptions from far more prescribers and pharmacies than the non-dual, non-disabled elderly. 
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The opioid utilization of pattern of disabled and dual-eligible enrollees could possibly be an 
outcome of their health status. Health systems and state-level policies may need to ascertain the 
health needs of these beneficiaries before implementing recipient restriction policies.  
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3 CHAPTER THREE: ASSOCIATIONS BETWEEN THE SPECIALTY OF OPIOID 
PRESCRIBERS AND OPIOID ADDICTION, MISUSE AND OVERDOSE 
OUTCOMES 
ABSTRACT  
BACKGROUND: Opioids are prescribed for acute and chronic pain by numerous specialties. We 
sought to examine the associations between prescriber specialty and the likelihood of opioid use 
disorder, misuse, and opioid overdose among Medicaid enrollees initiating opioid treatment. Our 
findings have implications for where to target efforts to educate both prescribers and patients about 
the safety of opioid use. 
METHODS: We conducted a longitudinal retrospective study using Pennsylvania Medicaid data 
(2007-2015). We constructed an incident cohort of 434,612 enrollees initiating new episodes of 
opioid treatment without history of opioid addiction or overdose at baseline. We attributed patients 
to one of ten prescriber specialties using the first opioid prescriber’s specialty, and alternatively, 
the dominant prescriber writing a majority of the patient’s opioid prescriptions. We estimated 
adjusted rate ratios (ARR) for three opioid-related risks (OUD, misuse, and overdose) adjusting 
for demographic and clinical characteristics.  
RESULTS: Patients who were first prescribed opioids by pain medicine/anesthesiology had 
higher ARR for OUD (1.53, 95% confidence interval (CI) =1.25, 1.88), misuse (1.62, 95% CI= 
1.36, 1.92), and overdose (2.12, 95% CI= 1.08, 4.14) compared to patients initiating opioid 
episodes with primary care practitioners (PCPs). Patients first prescribed opioids by physical 
medicine and rehabilitation specialists were also more likely to develop OUD (1.33, 95% CI=1.13, 
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1.57), misuse (1.61, 95% CI= 1.41, 1.84), and overdose (1.84, 95% CI= 1.07, 3.19) compared to 
patients initiating opioids with PCPs. Findings were largely similar when patients were attributed 
to specialty based on the dominant opioid prescriber specialty.  
CONCLUSION: We reported differences in adverse events associated with opioid use based on 
the provider specialties from whom opioid-naive Medicaid enrollees obtain their first prescription, 
and a majority of their prescriptions. These differences may arise from the clinical needs of patients 
seeking care from certain specialties or from the prescribing behaviors of particular specialties or 
both. These findings suggest that interventions directed towards patients and providers may benefit 
from targeting certain settings.  
KEYWORDS: Opioids, Prescriber Specialty, Medicaid, Overdose, Misuse, Opioid-Use Disorder 
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3.1 INTRODUCTION 
There are concerted efforts at the federal, state, and local level to mitigate the effects of 
opioid misuse and abuse and its adverse consequences including opioid overdose and death in the 
US. Opioid prescribing has been a particular focus of intervention and policy efforts. Several 
federal organizations and national associations for chronic pain have promulgated guidelines for 
initiating opioids and assessing risks/benefits for patients on long-term opioid therapy, typically 
used for chronic pain.58-61 States and health systems are implementing a myriad policies to address 
the opioid overdose epidemic, many of which have focused on influencing prescribing behavior 
through restrictions (e.g. limiting the days’ supply for initial opioid prescriptions) and prescription 
drug monitoring programs.62-65 
One of the challenges in improving the quality of opioid use is that opioids are prescribed 
in many settings (e.g. inpatient, outpatient, and post-acute), by many different specialties for both 
short and long-term pain treatment, and for many types of pain (e.g. back pain or arthritis/joint 
pain). Interventions to improve the quality of opioid prescribing may benefit from targeting these 
interventions to prescribers most likely to treat high-risk patients; however, the evidence-base for 
such targeting is limited. Recent evidence shows that certain characteristics of the initial opioid 
prescriptions (e.g. number of days’ supply) can determine the future course of opioid-related 
events including long-term dependency on opioids.66-70 Relatively little is known about the 
relationship between the specialty of the prescriber initiating opioid treatment and adverse opioid 
events. A recent study showed that a greater number prescriptions from primary care providers 
were associated with highest number of opioid overdose deaths compared to other specialists.71 It 
is not known whether the specialty of the opioid prescriber is correlated with non-mortality 
outcomes such as opioid use disorder (OUD) or misuse.  
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To inform the targeting of interventions to improve opioid prescribing and reduce the risks 
associated with opioid use, we examine the association between opioid prescriber specialty and 
opioid-related adverse outcomes among patients initiating a new episode of opioid treatment. To 
improve our understanding of the association between prescriber specialty and patient outcomes 
over the course of an episode of opioid treatment, we apply two methods for attributing patients to 
prescribers (and ultimately their specialty group). First, we identify the specialty of the prescriber 
responsible for the first opioid prescription. Second, we identify the specialty of the dominant 
prescriber responsible for the majority of opioid prescriptions for a particular patient. Our study 
setting is a large Medicaid program as Medicaid enrollees have a high risk of opioid overdose.57,72 
3.2 METHODS 
3.2.1 Description of data   
We conducted longitudinal analyses using Pennsylvania (PA) Medicaid data (January 2007 
through December 2015), which included data on all enrollees including fee-for-service and 
managed care enrollees. We obtained the data directly from the Department of Human Services 
(DHS). PA is one of largest Medicaid programs by expenditures and monthly enrollment.73,74 The 
demographics (except lower Hispanic population) and healthcare utilization trends in PA Medicaid 
are similar to those seen in other state Medicaid programs.75,76  
We used enrollment files to obtain beneficiary demographic characteristics (e.g. age, race, 
sex), reason for eligibility (e.g. disabled/chronically ill, children and families), enrollment 
duration, and insurance type (fee-for-service vs. managed care programs). We used the medical 
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claims (inpatient, outpatient, and professional) to obtain information on beneficiary diagnosis and 
procedure codes. The pharmacy claims included prescription characteristics such as the National 
Drug Code (NDC) from which we obtained type of opioid [short-acting opioid (SAO)/ long-acting 
opioid (LAO)], days’ supply, date of fill, and dose. We used the Medispan® data to obtain 
additional information on prescription characteristics (e.g. drug name, strength, and active 
ingredient by NDC).35 We used the unique provider identifiers (IDs) from the pharmacy files to 
identify provider specialties for this study.  
3.2.2 Study sample and cohort design 
Our analytic sample included enrollees aged ≥18 to ≤64 years, having at least one 
prescription for an opioid medication. Our analyses were limited to individuals not dually eligible 
for Medicare or those over 65 years of age since data on their prescription utilization cannot be 
observed in Medicaid. Furthermore, given likely differential opioid use patterns, we excluded 
enrollees with any cancer diagnosis, those residing in long-term care for ≥ 90 days, or enrollees 
using hospice services. 
We created an incident cohort of enrollees initiating opioid treatment episodes. The cohort 
selection is shown in the appendix (Figure B.1). An episode of opioid treatment started with the 
first opioid prescription (index event) and ended if there was a gap of ≥ 6 months between two 
consecutive opioid prescriptions.37 For patients with multiple opioid treatment episodes, we 
limited our primary analyses to the first observed episode. The index event was preceded by a 6-
month baseline period during which patients must have had: (1) six-months of continuous 
enrollment defined as enrollment of at least 15 days for six consecutive months, (2) no opioid 
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prescription fill, (3) no diagnosis of OUD or claim for prescription opioid or heroin overdose, and 
(4) no medication-assisted therapies for treating OUD.  
3.2.3 Outcome variables  
There were three primary outcomes of interest: OUD, opioid misuse, and opioid overdose. 
First, we constructed a dichotomous measure of diagnosis of OUD identified using diagnosis codes 
in medical claims (Table B.1) as defined by International Classification of Diseases, Ninth 
Revision (ICD-9) and the International Classification of Diseases, Tenth Revision (ICD-10) 
implemented near the end of our study period. Second, we used pharmacy claims to construct a 
measure of misuse based on a previously validated measure.38 Misuse is calculated by assigning a 
score to the following utilization measures: i) number of unique opioid prescribers (≤2 
prescribers=0, 3-4 prescribers=1, ≥5 prescribers=2), ii) number of unique pharmacies (≤2 
pharmacies=0, 3-4 pharmacies=1, ≥5 pharmacies=2), iii) days supplied of opioids of SAO (≤185 
days=0, 186-240 days=1, >240 days=2), and iv) days supplied for LAO (≤185 days=0, 186-240 
days=1, >240 days=2) during two consecutive 180-day periods. We used a dichotomized measure 
of misuse defined as a score ≥ 2. For lengthy opioid episodes with multiple two-180 day periods, 
the maximum misuse score was used. The third outcome was an overdose (due to prescription 
opioids) event that resulted in an emergency department (ED) visit or hospitalization identified 
using ICD-9/ICD-10 opioid poisoning codes observed in professional, outpatient or inpatient 
claims files.  
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3.2.4 Main explanatory variable  
The main explanatory variable -opioid prescriber specialty-required linking prescribing 
provider identifiers to information on specialty, and assigning patient-episodes to specialty groups 
using two approaches to attribution. First, we obtained the prescribing provider ID from the 
pharmacy claims which represent filled prescriptions, and the type of specialty from the provider 
file provided by the PA-DHS. Pharmacy claims were missing information on prescribing provider 
ID approximately 25% of the time. Our statistical approaches to handle this missing information 
is discussed below. 
After linking prescribing provider identifiers to the Medicaid provider file, we constructed 
10 categories of provider specialties based on highest frequency among opioid prescribers: 
Dentistry; Emergency Medicine (EM); Obstetrics/Gynecology (OB/GYN); Pain 
Medicine/Anesthesiology; Primary Care Practitioners (PCPs) which included Family/General 
Practice and Internal Medicine; Physical Medicine and Rehabilitation (PM&R); Podiatry; 
Psychiatry; Surgery; and other specialties. We could not differentiate pain medicine specialists 
from anesthesiologists since they were coded as one specialty in the provider file provided by PA-
DHS. The ‘other’ category included physician specialties that could not be classified in the above-
mentioned categories as well as a small number of advanced practice providers (e.g. nurse 
practitioners) who accounted for less than 1% of opioid prescriptions.  
We implemented two approaches to attribute patients to one of the 10 specialty groups. 
First, we attributed patients to a specialty based on the specialty of their first opioid prescriber (i.e., 
the provider responsible for writing the first opioid prescription filled). Our second alternative was 
to attribute patients to a specialty based on the specialty of the dominant prescriber in the first 
episode. For this, we counted the number of opioid fills per specialty group (aggregating if 
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necessary in the case of multiple unique prescribers of the same specialty). The specialty that 
prescribed the majority of opioid prescriptions in the episode was considered the dominant 
prescribing specialty. In some cases, there were equal number of prescription claims from two or 
more specialties. For this purpose, we created two additional dummy variables. One of the 
variables represented episodes that had ties between the number of prescriptions from PCPs and 
another non-PCP specialties (1=tie, 0= no tie), and another variable represented episodes that had 
ties between non-PCP prescriber specialties.  
3.2.5 Covariates 
We included patient-level socio-demographic characteristics such as age, gender, race 
(White or other), eligibility category (disabled/chronically ill, Medicaid expansion, families with 
children), insurance type (fee-for-service/managed care), and the following characteristics 
(yes/no) measured during the 6-month baseline prior to the index opioid fill: comorbid conditions 
including non-opioid substance use disorders (alcohol abuse/dependence, other drug 
abuse/dependence), mental health conditions (mood, anxiety, other mental health conditions), 
chronic pain conditions (back pain, neck pain, headache/migraine, and arthritis/join pain) 77, and 
baseline use of other benzodiazepine and muscle relaxants, and ED visits. Buprenorphine use in 
the episode was also included as a covariate. Finally, we included a Elixhauser comorbidity index 
which was modified based on the above conditions being removed.48 
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3.2.6 Statistical approach  
We conducted multivariable regression analyses using generalized linear models. To 
account for the varying length of episodes, we used the log link function and Poisson distribution 
where the offset variable was the natural log of the days of observation. We conducted two separate 
analyses using the alternate approaches to attributing patients to specialties (i.e., first vs. dominant 
prescriber). We compared adjusted rate ratios of the specialty groups to PCPs, the reference 
category.  
We observed that approximately 28% of the enrollees had missing provider IDs for the 
first prescription while 21% of the enrollees had missing provider IDs for majority of their 
prescriptions. We used two approaches handle missing data. First, we conducted a complete case 
analysis by excluding the prescription fills within episode with missing provider IDs. Second, we 
imputed the provider IDs using Multiple Imputation Chained Equations (MICE) and compared the 
results. The prescriber specialties were imputed based on all the covariates described above. Since 
the results from the complete-case and MICE analyses were largely similar, we present the 
complete-case analyses in the main paper while the results from the imputations are provided in 
the appendix (Appendix B). All analyses were conducted with SAS 9.4.49 This study was 
designated as exempt from University of Pittsburgh’s Institutional Review Board.  
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3.3 RESULTS 
3.3.1 Descriptive analyses 
The patient-level demographic characteristics are provided in Table 3.1. From 2007-2015, 
there were a total of 434,612 Medicaid enrollees initiating opioid treatment who met the 
inclusion/exclusion criteria. The average age was 30.7 [standard deviation (SD) =11.1] years. 
Enrollees were predominantly female (67.4%), white (58.1%), and/or living in urban locations 
(85.2%). A majority were enrolled in managed care organizations (93.7%) as opposed to fee-for-
service. The average duration of the first episode was 72.0 (SD=218.6) days with a median of 1 
day (minimum=1, maximum=3097 days). The overall prevalence of OUD, misuse and overdose 
in our study sample was 5%, 3.5%, and 0.2%, respectively. We observed that PCPs were the first 
opioid prescribers for 17.9% of patients, dentists were the first opioid prescribers for 20.7% of 
patients, while EM physicians were the first opioid prescribers for 15.7% of patients (Table 3.2). 
Pain medicine/anesthesiologists and PM&R specialists were the first opioid prescribers for 0.3% 
and 0.4% patients respectively. PCPs (19.1%), Dentists (21.5%), EM physicians (13.6%) were the 
dominant prescribers for majority of the patient episodes in our study sample.  
Table 3.1 Patient-level cohort characteristics 2007-2015 (N=434,612) 
Characteristics n (%) 
Age in years, Mean (SD) 30.7 (11.1) 
Female 292,751 (67.4) 
Race 
White 252,613 (58.1) 
Black 124,354 (28.6) 
Other 57,645 (13.2) 
Urban living area 370,426 (85.2) 
Type of eligibility at first episode 
Disabled/Chronically Ill  98,532 (22.7) 
Families with Children 288,220 (66.4) 
Expansion  26,678 (6.1) 
Other 21,451 (4.8) 
Type of health plan  
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Table 3.1 Continued  
Managed care 407,152 (93.7) 
Fee-for-service 27,460 (6.3) 
         Prevalence of outcomes 
OUD 21,700 (5.0) 
Misuse 15,386 (3.5) 
Overdose 981 (0.2) 
Duration of episode (days)  
Mean (SD) 72.0 (218.6) 
Median (Minimum-Maximum) 1 (1-3079) 
          Duration of follow-up (days) 
           Mean (SD)                                                                                               1030 (782.7) 
           Median (Minimum-Maximum)                                                                 801 (1-3106) 
OUD= Opioid use disorder, SD=standard deviation 
 
Table 3.2 Distribution of patient episodes across prescriber specialties under each attribution rule  
Index Prescribers Dominant Prescribers  
N % N % 
Dentistry 90,156 20.7 93,513 21.5 
Emergency Medicine 68,166 15.7 59,118 13.6 
Obstetrics/Gynecology 39,212 9.0 35,712 8.2 
Pain Medicine/Anesthesiology 1,068 0.3 1,491 0.3 
Physical Medicine and Rehabilitation 1,707 0.4 2,247 0.5 
Podiatry 2,313 0.5 2,970 0.7 
Primary Care 77,564 17.9 82,998 19.1 
Psychiatry 1,062 0.2 1,032 0.2 
Surgery 19,206 4.4 22,226 5.1 
Other 14,334 3.3 13,990 3.2 
Combination of other specialties a N/A  13,298 3.1 
Combination of primary care and other 
specialty b 
N/A  14,790 3.4 
Missing 119,824 27.6 91,227 21.0 
Total 434,612 100.00 434,612 100.00 
a Refers to episodes where more than one non-primary care specialty has equal prescription claims; b Refers to episodes where 
prescription claims from primary care and other non- primary care specialty are equal 
 
3.3.2 Associations between OUD and prescriber specialty  
The first set of analyses focused on the relationship between the index prescribing specialty 
in the episode and OUD. As seen in Table 3.3, for patients whose first opioid prescribers were 
from pain medicine/anesthesiology, the adjusted rate ratio (ARR) for OUD were 1.53, [95% 
confidence interval (CI)=1.25 1.88] compared to those patients whose first prescribers were PCPs. 
Similarly, for patients whose first prescribers were PM&R specialists, the ARR for OUD were 
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1.33 (95% CI=1.13, 1.57) compared to those patients whose first prescribers were PCPs. However, 
patients initiating opioid treatment with specialties more likely to treat acute pain had lower risk 
for OUD than patients initiating treatment with PCPs. The ARRs for OUD were 0.86 (95% 
CI=0.82, 0.90) for dentistry, 0.63 (95% CI=0.59, 0.68) for OB/GYN, 0.75 (95% CI=0.60, 0.94) 
for podiatry, and 0.74 (95% CI=0.69, 0.80) for surgery. The ARR for OUD for patients whose first 
prescribers were EM (1.02, 95% CI= 0.97, 1.07) or psychiatrists (1.08, 95% CI=0.90, 1.30) were 
not significantly different than for PCPs. 
Table 3.3 Adjusted rate ratios for associations between prescribing specialty and opioid use disorder 
 Index prescriber Dominant prescriber 
Parameters ARR            P ARR            P 
Dentistry  0.86 [0.82, 0.90] <.0001 0.83 [0.80, 0.87] <.0001 
Emergency Medicine 1.02 [0.97, 1.07] 0.48 1.00 [0.96, 1.05] 0.91 
Obstetrics/Gynecology 0.63 [0.59, 0.68] <.0001 0.55 [0.51, 0.59] <.0001 
Pain medicine/Anesthesiology 1.53 [1.25, 1.88] <.0001 1.31 [1.13, 1.52] 0.0004 
Physical Medicine and Rehabilitation 1.33 [1.13, 1.57] 0.0006 1.20 [1.06, 1.36] 0.0031 
Podiatry 0.75 [0.60, 0.94] 0.01 0.81 [0.68, 0.97] 0.02 
Psychiatry 1.08 [0.90, 1.30] 0.41 1.16 [0.98, 1.38] 0.09 
Surgery 0.74 [0.69, 0.80] <.0001 0.76 [0.71, 0.81] <.0001 
Other 0.86 [0.79, 0.94] 0.0005 0.89 [0.82, 0.96] 0.0026 
Combination of other specialtiesa N/A  0.84 [0.77, 0.91] <.0001 
Combination of primary care and 
other specialtyb 
N/A  1.01 [0.94, 1.08] 0.77 
Primary Care Reference  Reference  
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for 
varying length of exposure to opioid treatment; ARR= Adjusted Rate Ratios; a Refers to episodes where more than one non-
primary care specialty has equal prescription claims; bRefers to episodes where prescription claims from primary care and other 
non- primary care specialty are equal; Model is adjusted for demographic characteristics (age in years, race, urban/rural living 
area), enrollment characteristics (eligibility category, managed care/fee-for-service), baseline comorbid conditions (alcohol 
abuse/dependence, non-opioid drug abuse/dependence, adjustment disorders, mood disorders, anxiety disorders, back pain, neck 
pain, arthritis/join pain, headache/migraine, HIV/AIDS), and baseline use of benzodiazepines, muscle relaxants, and visits to 
emergency departments; Adjusted rates for all covariates included in this model are shown in Appendix B 
 
The second set of analyses focused on the relationship between the dominant prescribing 
specialty in the episode and OUD. These results were similar to the associations observed between 
index opioid prescribing specialty and OUD. As seen in Table 3.3, when the dominant prescribing 
specialty was pain medicine/anesthesiology the ARR for OUD was 1.31 (95% CI = 1.13, 1.52) 
relative to PCPs. Patients whose dominant opioid prescribers were PM&R specialists also had 
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higher ARR for OUD (1.20, 95 % CI = 1.06, 1.36) compared to those patients who obtained 
majority of their opioid prescriptions from PCPs. The ARR for OUD were significantly lower 
when patients obtained majority of their prescriptions from dentistry, OB/GYN, podiatry, and 
surgery compared to those patients who obtained majority of their opioid prescriptions from PCPs. 
The ARR for OUD for psychiatry was 1.16 (95 % CI= 0.98, 1.38), but the relationship was not 
significant at the p=0.05 level. Similarly, in case of ties, when patients obtained the same number 
of prescriptions from PCPs and other specialties, the ARR for OUD was 1.01 (95% CI=0.94, 1.08), 
but the relationship was not significant.  
3.3.3 Associations between misuse and prescriber specialty 
Patients whose first opioid prescriptions were written by pain medicine/anesthesiology had 
an ARR of 1.62 (95% CI=1.36, 1.92) for misuse relative to PCPs, while those by PM&R had an 
ARR of 1.61 (95% CI=1.41, 1.84) relative to index prescriptions by PCPs (Table 3.4). For index 
prescriptions from other specialties (EM, Dentistry, OB/GYN, Surgery, and Others), the ARR for 
misuse were significantly lower relative to index prescriptions from PCPs. The direction and 
magnitude of these associations between specialty and misuse were largely similar when patients 
were attributed to specialty groups on the basis of the dominant specialty, prescribing the majority 
of opioids in the episode.  
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Table 3.4 Adjusted rate ratios for associations between prescribing specialty and misuse 
 Index prescriber Dominant prescriber 
Parameters ARR P ARR  P 
Dentistry 0.39 [0.36, 0.41] <.0001 0.26 [0.25, 0.28] <.0001 
Emergency Medicine 0.78 [0.74, 0.82] <.0001 0.41 [0.39, 0.43] <.0001 
Obstetrics/Gynecology 0.46 [0.42, 0.50] <.0001 0.15 [0.13, 0.17] <.0001 
Pain Medicine/Anesthesiology 1.62 [1.36, 1.92] <.0001 1.86 [1.68, 2.07] <.0001 
Physical Medicine and Rehabilitation 1.61 [1.41, 1.84] <.0001 1.66 [1.51, 1.81] <.0001 
Podiatry 0.76 [0.62, 0.93] 0.01 0.97 [0.85, 1.11] 0.69 
Psychiatry 1.00 [0.81, 1.24] 0.99 0.76 [0.61, 0.94] 0.01 
Surgery 0.66 [0.61, 0.71] <.0001 0.67 [0.63, 0.71] <.0001 
Other 0.79 [0.72, 0.86] <.0001 0.62 [0.57, 0.67] <.0001 
Combination of other specialties a N/A 
 
0.43 [0.39, 0.48] <.0001 
Combination of primary care and other 
specialtyb  
N/A 
 
0.78 [0.73, 0.83] <.0001 
Primary Care Reference 
 
Reference 
 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying 
length of exposure to opioid treatment; ARR= Adjusted Rate Ratios; a Refers to episodes where more than one non-primary care specialty 
has equal prescription claims; b Refers to episodes where prescription claims from primary care and other non- primary care specialty are 
equal; Model is adjusted for demographic characteristics (age in years, race, urban/rural living area), enrollment characteristics (eligibility 
category, managed care/fee-for-service), baseline comorbid conditions (alcohol abuse/dependence, non-opioid drug abuse/dependence, 
adjustment disorders, mood disorders, anxiety disorders, back pain, neck pain, arthritis/join pain, headache/migraine, HIV/AIDS), use of 
burprenorphine, baseline use of benzodiazepines, muscle relaxants, and visits to emergency departments; Adjusted rates for all covariates 
included in this model are shown in appendix B 
 
3.3.4 Associations between overdose and prescriber specialty 
Similar to OUD and misuse, the ARR for overdose for patients whose first opioid 
prescriptions were from pain medicine/anesthesiology (2.12, 95% CI=1.08, 4.14) and PM&R 
(1.84, 95% CI=1.07, 3.19) were significantly higher relative to PCPs (Table 3.5).  The ARR for 
overdose when index prescriptions were obtained from dentistry (0.66, 95% CI= 0.53, 0.82), EM 
(0.74 95% CI=0.59, 0.91) and OB/GYN (0.37, 95% CI=0.25, 0.55) were significantly lower 
relative to PCPs. However, these results were sensitive to our attribution method; when the 
dominant specialty was used instead of the index specialty there were no significant differences 
between PCPs and either pain medicine/anesthesiology (1.04, 95% CI=0.57, 1.90) or PM&R (1.31, 
95% CI=0.84, 2.05) in the risk of overdose (Table 3.5).  
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Table 3.5 Adjusted rate ratios for associations between prescribing specialty and prescription opioid overdose 
 Index prescriber Dominant prescriber 
Parameters ARR P ARR P 
Dentistry  0.66 [0.53, 0.82] 0.0002 0.59 [0.48, 0.73] <.0001 
Emergency Medicine 0.74 [0.59, 0.91] 0.0049 0.62 [0.50, 0.77] <.0001 
Obstetrics/Gynecology 0.37 [0.25, 0.55] <.0001 0.31 [0.20, 0.47] <.0001 
Pain medicine/Anesthesiology 2.12 [1.08, 4.14] 0.03 1.04 [0.57, 1.90] 0.90 
Physical Medicine and Rehabilitation 1.84 [1.07, 3.19] 0.03 1.31 [0.84, 2.05] 0.23 
Podiatry 0.94 [0.38, 2.29] 0.89 0.63 [0.28, 1.42] 0.26 
Psychiatry 1.48 [0.76, 2.89] 0.25 1.19 [0.59, 2.40] 0.63 
Surgery 0.64 [0.45, 0.90] 0.01 0.59 [0.44, 0.80] 0.001 
Other 1.16 [0.84, 1.61] 0.36 0.85 [0.61, 1.19] 0.35 
Combination of other specialtiesa      N/A  0.70 [0.48, 1.02] 0.06 
Combination of primary care and other 
specialtyb 
N/A  0.93 [0.69, 1.25] 0.64 
Primary Care Reference  Reference  
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for 
varying length of exposure to opioid treatment; ARR= Adjusted Rate Ratios; a Refers to episodes where more than one non-primary 
care specialty has equal prescription claims; bRefers to episodes where prescription claims from primary care and other non- 
primary care specialty are equal; Model is adjusted for demographic characteristics (age in years, race, urban/rural living area), 
enrollment characteristics (eligibility category, managed care/fee-for-service) , baseline comorbid conditions (alcohol 
abuse/dependence, non-opioid drug abuse/dependence, adjustment disorders, mood disorders, anxiety disorders, back pain, neck 
pain, arthritis/join pain, headache/migraine, HIV/AIDS), use of burprenorphine, and baseline use of benzodiazepines, muscle 
relaxants, and visits to emergency departments; Adjusted rates for all covariates include in this model are shown in the appendix  
 
3.4 DISCUSSION  
We examined the association between opioid prescriber specialty and opioid-related risks 
among patients initiating treatment in a large Medicaid cohort. Our findings show that patients 
receiving opioid prescriptions from pain medicine/anesthesiology, PM&R, and PCPs are at greater 
risk. Patients treated with opioids by these specialties were consistently at greater risk for 
developing OUD and opioid misuse, although their risk of overdose was sensitive to how specialty 
group was assigned. Our findings have implications for the targeting of interventions to reduce 
opioid-related risks.  
Opioids are prescribed by many different specialties for both acute and chronic pain. Our 
results are in agreement with a previous study which showed that specialties more likely to 
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prescribe opioids for chronic pain had higher risks of opioid related deaths.71 Using data from the 
medical examiner, prescription drug monitoring program and controlled substance database from 
the state of Utah, the study found that anesthesiologists, pain medicine specialists, and physicians 
from PM&R has 2.0, 2.6, 2.1 times higher opioid-related fatalities respectively for every 1000 
prescriptions compared to internal medicine physicians.71 In addition to mortality-related 
outcomes, our study also found higher ARR for non-mortality outcomes of OUD and misuse 
among specialties that prescribe opioids for chronic pain after adjusting for diagnoses of chronic 
pain. The literature on opioid prescribing by specialists more likely to prescribe opioids for acute 
pain - dentists, OB/GYN, and orthopedic surgeons - has been mixed. Although some studies have 
reported higher likelihood of prescribing an opioid by prescribers from dentistry and surgery 
compared to those from family medicine and general practice71,78,79, the opioid-related fatalities 
among patients who received prescriptions from dentistry, OB/GYNs, and orthopedic surgery is 
reported to be lower relative to those receiving prescriptions from internal medicine physicians.71 
In our study, we observed that incident patients newly prescribed opioids from dentistry, OB/GYN, 
and surgery had significantly lower ARR of OUD, misuse or overdose compared to those who 
received their prescriptions from PCPs. Recent research suggests that emergency medicine is a 
potential gateway to long-term opioid use.67,80 In this study, we observed that ARR for misuse and 
overdose were significantly lower when emergency medicine physicians were the first or dominant 
prescribers in an episode than PCPs. 
We were not able to identify the underlying causes of differences in opioid-related risks by 
specialty which may be related to significant differences in patient factors, provider behavior or 
both. Patients receiving opioid treatment from pain medicine and PM&R specialists are more 
likely to have chronic non-cancer pain81 and may have complex physical, behavioral and 
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psychosocial issues often requiring inter-disciplinary care.46,82,83 Evidence on the quality of opioid 
prescribing by pain management and PM&R specialists is scarce. Interestingly, a prior study 
showed a steady increase in rates of opioid prescribing by these two specialties between 2007 to 
2012.78 We observed that pain management and PM&R specialists were the index or dominant 
prescribers for a small proportion of patients. By contrast, PCPs were index or dominant 
prescribers for a majority of patients in our study sample and had higher risk of adverse events 
compared to other acute pain treating specialties (dentistry, surgery, OB/GYN). Our findings 
highlight that policies can potentially be targeted toward specific physician specialties to allow 
early opportunity to intervene by screening patients, suggesting behavior changes or referring 
high-risk cases to medication treatment. Given the high-volume of opioid prescribing among 
specialties like PCPs71,78,79, effective targeting of interventions may, in turn, depend on factors 
such as patient-volume, patient-risk for adverse outcomes, or a combination of both. More studies 
are required to better understand how such factors can influence the targeting of interventions.  
A number of efforts are underway to reduce adverse consequences of opioid exposure. In 
2014, the PA-DHS established Centers of Excellence with the aim of providing coordinated care 
to patients with OUD.84 These efforts can potentially be expanded to patients seeking care from 
specialists from pain medicine and PM&R and PCPs. Health systems could monitor prescribing 
practices and communicate with prescribers about aberrant prescribing patterns. In addition, health 
systems could also encourage increased physician participation in continuing education programs 
which are being organized by the Substance Abuse and Mental Health Services Administration.85 
Our study helps in contributing evidence that could be used by organizations currently developing 
strategies for pain management.  
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3.4.1 Strengths and Limitations 
Study strengths include our focus on patients initiating opioid treatment with no history of 
OUD or overdose in the baseline period, detailed information on prescriber specialty, and two 
approaches to attributing patient-episodes to specialty groups. The results of this study, however, 
should be viewed in light of some key limitations. First, although we adjust for patient level 
comorbidities, demographic, and enrollment variables, there are several unmeasured confounders 
(e.g. severity of pain) that cannot be accounted for given the nature of observational data. Second, 
limiting our analyses to only PA Medicaid claims reduces the external validity of our findings. 
Third, our data cannot identify events that occur outside of the health system. For example, cash 
payments for prescriptions cannot be captured if enrollees choose not to use insurance and we 
cannot determine which prescription fills are subject to diversion. Also, we measure overdose 
events (fatal and non-fatal) that received medical attention but do not capture overdoses in the 
community. However, these issues are observed in most health care insurance claims since they 
do not capture clinical information that can help in validating medication consumption. Fourth, 
OUD diagnosis is often under-coded in claims data.86 Patients receiving an OUD diagnosis may, 
in fact, represent a unique population of patients who have talked to their physician about their 
OUD or their aberrant prescription use may have alerted their physicians. Finally, we imputed the 
provider specialties when provider IDs were missing. Although the results were largely similar to 
the complete-case analysis, imputations may not accurately reflect real-world scenarios.  
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3.5 CONCLUSIONS 
Our findings indicate that patients receiving opioid prescriptions from pain 
medicine/anesthesiology, PM&R, and PCPs are at greatest risk of OUD, misuse or overdose. The 
results of this paper provide evidence for targeted physician and health-systems level interventions 
to reduce adverse effects of over prescribing of opioids. 
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4 CHAPTER FOUR: MOOD DISORDERS, ANTIDEPRESSANTS AND OPIOID USE:  
THE ROLE OF ADHERENCE 
ABSTRACT 
BACKGROUND: Patients with psychiatric illnesses are both more likely to be prescribed an 
opioid medication and experience adverse consequences of opioid exposure such as abuse, misuse, 
and overdose. Many antidepressants promote analgesia, and successful treatment of depression 
reduces the bothersomeness of pain. Many patients, however, do not take antidepressant 
medications as prescribed and discontinue their use prematurely. Describing the link between 
antidepressant medication adherence (a modifiable behavior) and subsequent opioid use may 
provide insight into another approach to reduce the epidemic of opioid abuse. This study examines 
the relationship between adherence to antidepressant medications among individuals with mood 
or anxiety disorders and its association with opioid use. 
METHODS: We conducted a longitudinal retrospective study using Pennsylvania Medicaid data 
(2007-2015). We constructed a cohort of 18 to 64-year-old enrollees initiating antidepressant 
treatment who had a diagnosis for major depressive disorders (MDD) or anxiety disorders. We 
measured adherence using proportion of days covered (PDC) over a 180-day period after initiation 
of antidepressant treatment and censored our follow-up time to two years after end of adherence 
measurement period. We conducted Cox proportional hazards regression analyses to examine the 
effect of adherence on opioid use. 
RESULTS: Our findings show that there were no significant differences in adjusted hazards for 
opioid use (0.94, 95% CI=0.87, 1.01) among the adherent (PDC ≥ 80%) and non-adherent 
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enrollees (PDC <80%) with MDD and no cancer. However, using the multi-category definitions 
of adherence and PDC<20% as reference category, the adjusted hazard ratios for opioid use were 
as follows: 20% ≤ PDC <40% = 0.76, (95% CI= 0.68, 0,85), 40% ≤ PDC <60% = 0.80, (95% CI= 
0.70, 0.90), 60% ≤ PDC <80% = 0.79 (95% CI= 0.70, 0.90, and PDC ≥ 80% = 0.77 (95% CI = 
0.70, 0.86). Proportional hazards assumptions for these models were violated. For enrollees with 
anxiety and no cancer, the adjusted hazards of opioid use were significant lower (0.84, 95% CI= 
(0.72, 0.99) for the 40% ≤ PDC <60% category (reference = PDC<20%). Among enrollees with 
MDD and anxiety and any cancer, there were no significant relationships between adherence and 
opioid use. 
CONCLUSION: Within the limitations of our study, we observed that enrollees with MDD and 
no cancer who achieve ≥ 20% PDC have significantly lower baseline hazard ratios for opioid use 
than enrollees with PDC<20%. Further research is required to confirm our findings. 
KEYWORDS: Mood disorders, Depression, Anxiety, Antidepressants, Adherence, Opioids 
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4.1 INTRODUCTION 
Significant policy efforts are underway to mitigate the opioid epidemic in the United 
States. Opioid prescribing has been an important focus of policy interventions.2,58 It is 
established that not only is there high comorbidity among depression and anxiety with chronic 
non-cancer pain87-93, but individuals with these psychiatric diseases are more likely to be 
prescribed opioids.10,12,94-98 More troubling, patients with psychiatric illnesses who are prescribed 
opioids experience an elevated risk of adverse consequences use such as abuse, misuse, and 
overdose.99-104 Increased opioid prescribing among these patients with chronic pain and 
depression and/or anxiety is referred to as “adverse selection,”105,106 and is inconsistent with 
professional prescribing and clinical care guidelines.58  
There is substantial evidence to support the bi-directional nature of mood disorders and 
pain.107-113 Of specific interest in the context of the opioid epidemic is the pre-existence of mood 
disorders and subsequent onset of pain. Patients with depression experience abnormalities of the 
serotonergic and noradrenergic systems, which has been suggested to play a role in the 
development of physical pain symptoms.114 Evidence from placebo-controlled studies shows that 
treatment with antidepressants can mitigate these abnormalities and help in improving pain 
symptoms.14,15 A less understood relationship and an emerging line of inquiry is the adherence to 
antidepressant medications among individuals with mood disorders and its association with 
opioid use.  
In this study, we examined the associations between adherence to antidepressant therapy 
among individuals with mood disorders and future opioid use. To inform the targeting of 
interventions aimed at addressing the opioid epidemic, it is important to understand in what 
subgroups of patients unnecessary exposure of opioids can be minimized. Studies have shown 
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that adherence to antidepressant medications is usually low ranging from 13% to 56%.115 If high 
adherence to antidepressants is associated with reduce use of opioid medications, then 
interventions can be targeted toward increasing adherence to antidepressant medications. The 
setting for this study is a large Medicaid program as Medicaid enrollees have high prevalence of 
comorbid mental illnesses and are also at a higher risk for adverse outcomes of opioid use.57,72 
4.2 METHODS 
4.2.1 Description of data  
We conducted retrospective longitudinal analyses using Pennsylvania (PA) Medicaid data. 
We obtained data on all enrollees in either the fee-for-service or and managed care programs 
between January 2007 and December 2015 directly from Department of Human Services (DHS). 
PA is one of largest Medicaid programs in the US by expenditures and monthly enrollment.73,74 
The demographic characteristics (except lower Hispanic population) and healthcare utilization 
trends in PA Medicaid are similar to those seen in other state Medicaid programs.76,102 
We used enrollment files to obtain beneficiary demographic characteristics (e.g. age, race, 
sex), reason for eligibility (e.g. disabled/chronically ill, children and families), enrollment 
duration, and insurance type (fee-for-service vs. managed care programs). We used the medical 
claims (inpatient, outpatient, and professional) to obtain information on beneficiary diagnosis and 
procedure codes. The pharmacy claims included prescription characteristics such as the National 
Drug Code (NDC) from which we obtained days’ supply, date of fill, and dose. We used the 
  50 
Medispan® data to obtain additional information on prescription characteristics including drug 
name, strength, and active ingredient by NDC.35  
4.2.2 Study sample and cohort design 
Our analytic cohort included enrollees aged ≥18 to ≤64 years, who were not dually eligible 
for Medicare since we could not observe data on their prescription utilization. In addition, we 
excluded enrollees who met the following criteria: 1) receiving a diagnosis for bipolar 
disorders/schizophrenia, other psychosis-related disorders, paranoid state, drug-induced 
depression depressive-type psychosis, Alzheimer’s disease, Parkinson’s disease, and dementia, 
and 2) residing in long-term care for ≥ 90 days, or enrollees using hospice services. The 
International Classification of Diseases, Ninth Revision (ICD-9) and International Classification 
of Diseases, Tenth Revision (ICD-10) codes for the exclusion diagnoses are provided in the 
appendix (Appendix C).  
We created two separate cohorts of enrollees with a diagnosis of major depressive disorders 
(MDD) or anxiety disorders initiating antidepressant treatment. The cohort selection is shown in 
the appendix (Figure C.1). The first prescription for an antidepressant medication was treated as 
an index event. The index event was preceded by a 6-month baseline period during which enrollees 
had to meet the following criteria: having six-months of continuous enrollment defined as 
enrollment of at least 15-days for six consecutive months and no prescription fills for 
antidepressants or opioids. Enrollees were required to have a diagnosis of MDD or anxiety disorder 
at some point during the six-months prior to the index antidepressant fill or within 30 days after 
antidepressant the index fill (Appendix Figures C.2 and C.3). Since there was a significantly high 
prevalence of cancer in both the MDD (n=3,733, 25.4%) and anxiety cohorts (n=2,597; 25.5%) 
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(Table 4.1), we stratified our analyses into the follow four sub-groups: 1) MDD and no cancer, 2) 
MDD and presence any cancer, 3) anxiety disorders and no cancer, 4) anxiety disorders and 
presence of any cancer. 
4.2.3 Main explanatory variable 
The main independent variable for the analysis was adherence to antidepressant 
medications. Adherence was measured using proportion of days covered (PDC). The PDC is 
defined as the number of days covered with antidepressants between the first and the last 
prescription divided by the required duration of therapy. We chose a six-month time frame since 
it is considered as the minimum required duration of therapy to achieve both the acute and 
maintenance phase of treatment.116 The PDC calculations also accounted for the number of days 
of overlap for individuals taking >1 antidepressant concurrently and were capped at 1.0. The 
Pharmacy Quality Alliance has endorsed using of PDC117 as superior to other adherence measures 
such as the medication possession ratio as it may over-estimate the true prescription fill rate. We 
used two definitions of adherence for our analysis. First, we used the conventional dichotomous 
definition of adherence, where patients achieving ≥80% PDC are considered adherent. The 80% 
threshold is widely used. However, studies have found this threshold to be arbitrary and not always 
sensitive to clinically important differences in the levels of adherence.118 We therefore used 
another categorical measure of adherence where we grouped adherence into the following five 
categories: (PDC <20%, 20%≤PDC<40%, 40%≤PDC<60%, 60%≤PDC<80%, PDC ≥ 80%).  
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4.2.4 Outcome variable  
Our outcome variable of interest was the time to the first prescription of oral, transdermal, 
or submucosal opioid medication. We measured opioid use in the 180 days after the measurement 
period for antidepressant adherence had ended.  
4.2.5 Covariates 
We included patient-level socio-demographic characteristics such as age, gender, race 
(White, Black or Other), eligibility category during the first opioid prescription 
(disabled/chronically ill, families with children, other), and insurance type (fee-for-
service/managed care). We also included indicators for the following comorbid conditions for 
which ICD-9 codes were present during the six-month baseline period prior to the index opioid 
fill: substance use disorders (alcohol abuse/dependence, non-opioid drug abuse/dependence), 
mental health conditions (adjustment disorders, other mental health conditions), chronic pain 
conditions (back pain, neck pain, headache/migraine, and arthritis/join pain).77 We also included 
a modified Elixhauser comorbidity index48 which did not include those conditions identified 
separately above.  
4.2.6 Statistical Analyses 
The association between adherence to antidepressants and opioid use was estimated using 
Kaplan Meier survival plots. We used the long-rank tests for equality of survival functions to test 
for differences in the survival curves. We conducted Cox proportional hazards regression and 
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estimated adjusted hazard ratios and 95% confidence intervals (CI) to assess the relationship 
between adherence and opioid use adjusting for the above-mentioned covariates. We undertook a 
step-wise approach to assess the relationship between the adherence measures and opioid use in 
the presence of covariates. We first analyzed uni-variable or unadjusted models, where we 
evaluated the relationship between adherence measures and opioid use. Next we explored the 
impact of adjusting for i) demographic variables, ii) enrollment variables and iii) other comorbid 
conditions on opioid use. Proportionality assumptions were tested using the interaction of the 
adherence measures with follow-up time. Since a nine-year time duration would be too long to 
explore the impact of adherence on opioid use, for our main analyses, we censored the follow-up 
time to a two-year period after the end of the adherence measurement period. We also conducted 
sensitivity analyses, where the follow-up period was censored to one-year. All analyses were 
conducted with SAS 9.4. and Stata.49,119 This study was designated as exempt from University of 
Pittsburgh’s Institutional Review Board.  
4.3 RESULTS 
4.3.1 Characteristics of study cohort 
4.3.1.1 MDD cohort 
The demographic characteristics of the MDD and anxiety cohort are provided in Table 4.1. 
From 2007-2015, there were a total of 14,670 Medicaid enrollees initiating antidepressant 
treatment who met the inclusion/exclusion criteria for the MDD cohort. Of these, 45.2% (n=6,630) 
filled at least one opioid prescription after antidepressant adherence was measured (i.e. 180-days 
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initiation of antidepressant therapy). The average age of the cohorts with and without opioid use 
was 33.8 (SD=11.7) and 33.7 (SD=12.4) years respectively (p=0.54). The group with opioid use 
had significantly higher proportion of females (opioid use, 80.2% vs. no opioid use, 68.5%; p 
<0.0001), managed care enrollees (opioid use, 97.6 % vs. no opioid use, 92.3%; p <0.0001), and 
those qualifying for Medicaid under the disabled/chronically ill category (opioid use, 27.3% vs. 
no opioid use, 25.3%; p=0.007) and families with children (opioid use, 65.5% vs. no opioid use, 
58.7%; p <0.0001) categories. In addition, there was a significantly (p<0.0001) higher prevalence 
of any cancer among individuals with opioid use (34.6%) compared to the non-opioid use (17.9%).  
Table 4.1 Characteristics of enrollees with major depressive disorders and anxiety 
 
4.3.1.2 Anxiety cohort 
The demographic characteristics of the cohort with anxiety were similar to the MDD 
cohort. From 2007-2015, there were a total of 10,167 Medicaid enrollees initiating antidepressant 
treatment who met the inclusion/exclusion criteria. Of these, 41.5% (n=4,217) had at least one 
 MDD cohort Anxiety cohort  
Opioid use 
(n=6,630) 
No opioid use 
(n=8,040) 
P Opioid use 
(n=4,217) 
No opioid use 
(n=5,950) 
P 
Demographics 
Age at first 
antidepressant 
prescription, mean (SD) 
33.8 (11.7) 33.7 (12.4) 0.54 32.8 (11.1) 32.6 (12.0) 0.32 
Female, n (%) 5,318 (80.2) 5,506 (68.5) <0.0001 3,346 (79.4) 4,110 (69.1) <0.0001 
Urban living area, n (%) 5,422 (81.8) 6,570 (81.7) 0.93 3,368 (79.9) 4,767 (80.1) 0.76 
White, n (%) 4,299 (64.8) 5,752 (71.5) <0.0001 3,196 (75.8) 4,680 (78.6) 0.0007 
Black, n (%) 1,286 (19.4) 1,177 (14.6) <0.0001 572 (13.6) 629 (10.6) <0.0001 
Other, n (%) 1,045 (15.8) 1,111 (13.8) 0.0009 449 (10.6) 641 (10.8) 0.84 
Eligibility categories 
Disabled/Chronically 
Ill, n (%) 
1,808 (27.3) 2,033 (25.3) 0.007 1,037 (24.6) 1,448 (24.3) 0.77 
Families with Children, 
n (%) 
4,340 (65.5) 4,717 (58.7) <0.0001 2,885 (68.4) 3,509 (59.0) <0.0001 
Other, n (%) 482 (7.3) 1,290 (16.0) <0.0001 295 (7.0) 993 (16.7) <0.0001 
Managed care 
enrollees, n (%) 
6,472 (97.6) 7,423 (92.3) <0.0001 4,118 (97.7) 5,511 (92.6) <0.0001 
Any Cancer, n (%) 2,292 (34.6) 1,441 (17.9) <0.0001 1,469 (34.8) 1,128 (19.0) <0.0001 
MDD = Major Depressive Disorders; SD = standard deviation; Differences between categorical variables were tested using chi-square 
tests. Differences between continuous variables were tested using independent-samples t-tests. 
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opioid prescription fill after antidepressant adherence was measured (i.e. 180-days initiation of 
antidepressant therapy). The average age of the cohorts with and without opioid use was 32.8 
(SD=11.1) and 32.6 (SD=12.0) years respectively (p=0.32). The group with opioid use had 
significantly higher proportion of females (opioid use, 79.4% vs. no opioid use, 69.1%; p <0.0001), 
managed care enrollees (opioid use, 97.7% vs. no opioid use, 92.6%; p <0.0001), and those 
qualifying for Medicaid under the families with children eligibility category (opioid use, 68.4% 
vs. no opioid use, 59.0%; p <0.0001). There was a significantly (p<0.0001) higher prevalence of 
any cancer among individuals with opioid use (34.8%) compared to the non-opioid use group 
(19.0%).  
4.3.2 Adherence measures 
4.3.2.1 MDD cohort  
As explained in the methods section, we stratified our analyses based on the presence of 
cancer in both the MDD and anxiety cohorts. In the MDD cohort, there were 10,937 (74.5%) 
beneficiaries who did have cancer. Among these enrollees, using the dichotomous definition of 
adherence (PDC ≥80%), we observed that there were significantly fewer adherent enrollees in the 
opioid use sub-group (opioid use sub-group =31.9 % vs. no opioid use sub-group =36.0%, 
p<0.0001) (Table 4.2). Among enrollees with MDD and any cancer (n=3,733; 25.5%) there was 
a significantly lower proportion of enrollees meeting PDC ≥80% criterion (opioid use sub-group 
=37.5% vs. no opioid use sub-group =40.3%, p=0.09). 
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Table 4.2 Distribution of enrollees according to categories of proportion of days covered  
MDD COHORT ANXIETY COHORT 
NON-CANCER   
Opioid use 
(n=3,142) 
No opioid use 
(n=7,795) 
P Opioid use  
(n=2,046) 
No opioid use 
(n=5,524) 
P 
Using continuous measure of PDC 
Mean (SD)* 0.57 (0.30) 0.61 (0.29) <0.0001 0.60 (0.30) 0.62 (0.29) 0.0005 
Median (Min-Max)φ 0.50 (0.03-1.00) 0.64 (0.01-1.00) <0.0001 0.60 (0.05-1.00) 0.67 (0.02-1.00) 0.004 
Using dichotomous categories of PDC  
PDC <80% 2,139 (68.1) 4,986 (64.0) <0.0001 1,319 (64.5) 3,363 (60.9) 0.0043 
PDC ≥80% 1,003 (31.9) 2,809 (36.0) 727 (35.5) 2,161 (39.1) 
Using multiple categories of PDC 
PDC <20% 544 (17.3) 848 (10.9) <0.0001 318 (15.5) 613 (11.1) <0.0001 
20% ≤ PDC <40% 660 (21.0) 1,749 (22.4) 411 (20.1) 1,145 (20.7) 
40% ≤ PDC <60% 504 (16.0) 1,213 (15.6) 294 (14.4) 824 (14.9) 
60% ≤ PDC <80% 431 (13.7) 1,176 (15.1) 296 (14.5) 781 (14.1) 
PDC ≥80%   1,003 (31.9) 2,809 (36.0) 727 (35.5) 2,161 (39.1) 
CANCER  
 Opioid use 
(n=1,679) 
No opioid use 
(n=2,054) 
P Opioid use  
(n=1,028) 
No opioid use 
(n=1,569) 
P 
Using continuous measure of PDC 
Mean (SD)* 0.61 (0.30) 0.63 (0.30) 0.047 0.59 (0.31) 0.63 (0.30) 0.004 
Median (Min-Max)φ 0.63 (0.01-1.00) 0.67 (0.03-1.00) <0.0001 0.61 (0.01-1.00) 0.67 (0.02-1.00) 0.02 
Using dichotomous categories of PDC 
PDC <80% 1049 (62.5) 1,227 (59.7) 0.09 654 (63.6) 926 (59.0) 0.02 
PDC ≥80% 630 (37.5) 827 (40.3) 374 (36.4) 643 (41.0) 
Using multiple categories of PDC 
PDC <20% 265 (15.8) 261 (12.7) 0.05 175 (17.0) 210 (13.4) 0.06 
20% ≤ PDC <40% 297 (17.7) 393 (19.1) 190 (18.5) 280 (17.8) 
40% ≤ PDC <60% 252 (15.0) 297 (14.5) 143 (13.9) 214 (13.6) 
60% ≤ PDC <80% 235 (14.0) 276 (13.4) 146 (14.2) 222 (14.2) 
PDC ≥80%   630 (37.5) 827 (40.3) 374 (36.4) 643 (41.0) 
MDD = Major Depressive Disorders; PDC = Proportion of days covered; *Mean PDC compared using independent two-sample t-tests; φ Medians compared using 
Wilcoxon rank sum tests.  
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4.3.2.2 Anxiety cohort  
We observed similar findings in the anxiety cohort. There were 7,570 (74.4%) who did 
not have cancer. Among these enrollees, there were significantly fewer adherent enrollees (PDC 
≥80%) who had opioid use (opioid use sub-group=35.5 % vs. no opioid use sub-group=39.1%, 
p<0.0001). Similarly, among enrollees with anxiety and presence of any cancer, the opioid use 
sub-group had significantly fewer adherent enrollees compared to the non-opioid use sub-group 
(opioid use sub-group =36.4 % vs. no opioid use sub-group =41.0%, p=0.02). 
4.3.3 Kaplan-Meier estimates  
4.3.3.1 MDD cohort 
We constructed Kaplan-Meier survival plots and conducted log-rank tests for equality of 
survivor functions to study the relationship between adherence to antidepressant therapy and 
opioid use. In the MDD cohort without cancer (Figure 4.1A), the median time for opioid use in 
the MDD and no cancer cohort was 231.5 days (minimum=1, maximum= 731). There were 
statistically significant differences in the Kaplan-Meier survival curves using both the 
dichotomous (χ2 (1) = 13.2, p=0.0002) and multi-category definitions of adherence (χ2 (4) = 81.2, 
p=<0.0001) (Figure 4.1B). For the MDD and any cancer cohort, the median time to opioid use 
was 221days (minimum=1, maximum=728). There were no statistically significant differences in 
the Kaplan-Meier survival curves in the MDD cohort with any cancer using both the dichotomous 
(χ2 (1) = 1.6, p=0.21) and multi-category definitions of adherence (χ2 (4) = 7.1, p=0.13) (Figures 
4.1C and 4.1D).  
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4.3.3.2 Anxiety cohort 
For the cohort with anxiety and no cancer, the median time to opioid use was 210 days. 
There were statistically significant differences (χ2 (1) = 0.69, p=0.005) in the survival curves using 
the dichotomous (Figure 4.2A) and multi-category (χ2 (4), = 28.3, p<0.0001) definitions of 
adherence (Figure 4.2C). In the cohort with anxiety and any cancer, there were statistically 
significant differences (χ2 (4), = 4.72, p=0.03) in the survival curves using the dichotomous 
definition of adherence (Figures 4.2B), but the differences were not significant using the multi-
category definition of adherence, (χ2 (4), = 7.42, p=0.12) (Figures 4.2D). 
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Figure 4.1 Unadjusted Kaplan Meier estimates of opioid use among enrollees with major depressive disorders 
Note: Unadjusted Kaplan Meier estimates of opioid use among enrollees with major depressive disorders classified using: (A) dichotomous 
definition of adherence (PDC ≥80%) among enrollees with no cancer, (B) multi-category definition of adherence among enrollees with no cancer, 
(C) dichotomous definition of adherence (PDC ≥80%) among enrollees with cancer, and (D) multi-category definition of adherence among enrollees 
with cancer. Note: The differences in the survival curves were tested using the log-rank tests for equality of survivor functions.  
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Note: Unadjusted Kaplan Meier estimates of opioid use among enrollees with anxiety disorders classified using: (A) dichotomous definition of 
adherence (PDC ≥80%) among enrollees with no cancer, (B) dichotomous definition of adherence (PDC ≥80%) among enrollees with cancer, 
(C) multi-category definition of adherence among enrollees with no cancer, and (B) multi-category definition of adherence among enrollees 
with cancer . Note: Note: The differences in the survival curves were tested using the log-rank tests for equality of survivor functions. .  
 
Figure 4.2 Unadjusted Kaplan Meier estimates of opioid use among enrollees with anxiety disorders 
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4.3.4 Cox-proportional hazards  
We conducted Cox-proportional hazards regressions to assess the relationship between 
adherence to antidepressants and opioid use adjusting for demographic and enrollment 
characteristics and presence of comorbid mental illness and pain.  
4.3.4.1 MDD cohort  
We observed no significant differences in adjusted hazards for opioid use (0.94, 95% 
CI=0.87, 1.01) among the adherent and non-adherent enrollees using the ≥ 80% PDC criterion in 
the MDD and no cancer sub-group (Table 4.3). However, using the multi-category definitions of 
adherence and PDC<20% as reference category, adjusted hazard ratios for opioid use were as 
follows: 20% ≤ PDC <40% = 0.76, (95% CI= 0.68, 0,85), 40% ≤ PDC <60% = 0.80, (95% CI= 
0.70, 0.90), 60% ≤ PDC <80% = 0.79 (95% CI= 0.70, 0.90), and PDC ≥ 80% = 0.77 (95% CI = 
0.70, 0.86) (Table 4.4). The proportional hazards assumptions for these models were not met. In 
the MDD and cancer sub-group, the adjusted hazards of opioid use were significantly lower (0.84, 
95% CI= 0.71, 0.99) only for the 20% ≤ PDC <40% category (reference = PDC<20%). In the 
sensitivity analyses we observed that enrollees achieving 20% ≤ PDC <40% at one-year of follow-
up had significantly lower adjusted hazards of opioid use (0.86, 95% CI=0.74, 0.99) (Appendix 
Table C.2). 
4.3.4.2 Anxiety cohort  
Using the ≥ 80% PDC criterion, there were no significant differences in opioid use among 
the adherent and non-adherent enrollees (Adjusted Hazard Ratios=0.97; 95% CI= 0.89, 1.07). The 
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adjusted hazards of opioid use were significant lower (0.84, 95% CI= (0.72, 0.99) for the 40% ≤ 
PDC <60% category (reference = PDC<20%). Using both the dichotomous (0.92, 95% CI= 0.80, 
1.05) and multi-category (0.85, 95% CI=0.71, 1.02) definitions for adherence, we found no 
significant differences in the adjusted hazards for opioid use between adherent and non-adherent 
enrollees in the anxiety cohort who had any cancer.   
 
Table 4.3 Results of Cox proportional hazards models among individuals with major depressive and anxiety 
disorders - effect of 80% PDC threshold on opioid use  
MDD Anxiety 
 No cancer Cancer No cancer Cancer 
Adherence (Ref= PDC 
<80%) 
0.87 (0.80, 0.93) * 0.94 (0.85, 1.04) 0.88 (0.80, 0.96) * 0.87 (0.77,0.99) * 
Adherence+ 
Demographic  
0.89 (0.83, 0.96) * 0.97 (0.88, 1.08) 0.90 (0.82, 0.99) * 0.87 (0.76, 0.99) * 
Adherence + 
Demographic + 
Enrollment 
0.91 (0.84, 0.99) * 1.00 (0.99, 1.00) 0.93 (0.85, 1.02) 0.88 (0.77, 0.99) * 
Adherence + 
Demographic + 
Enrollment + Comorbid 
mental health and pain 
0.94 (0.87, 1.01) 1.02 (0.92, 1.13) 0.97 (0.89, 1.07) 0.92 (0.80, 1.05) 
Demographic covariates = Age in years, Gender, Race (White, Black or Other), Place of residence (Urban/Rural); Enrollment 
covariates= Managed care/fee-for-service, Eligibility categories (Disabled/Chronically Ill, Expansion, Families with Children, 
Others); Comorbid mental health conditions = alcohol and substance abuse disorders, adjustment disorders, other mental health 
conditions; Comorbid pain conditions = back pain, neck pain, arthritis/joint pain, headache/migraine; MDD = Major Depressive 
Disorder; PDC=Proportion of days covered; Bold refers to non-violation of proportional hazards assumption; * = p<0.05 
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Table 4.4 Results of Cox proportional hazards models among individuals with major depressive and anxiety disorders - effect of multiple adherence 
categories on opioid use  
                 MDD 
 
                     Anxiety  
No cancer Cancer No cancer Cancer 
Adherence variables only 
20% ≤ PDC <40% 0.67 (0.59, 0.75) ** 0.82 (0.70, 0.97) * 0.74 (0.64, 0.86) ** 0.87 (0.71, 1.07) 
40% ≤ PDC <60% 0.72 (0.64, 0.82) ** 0.90 (0.76, 1.07) 0.74 (0.63, 0.87) * 0.86 (0.69, 1.08) 
60% ≤ PDC <80% 0.65 (0.58, 0.74) ** 0.91 (0.77, 1.09) 0.78 (0.67, 0.92) * 0.88 (0.70, 1.09) 
PDC ≥80%   0.64 (0.58, 0.71) ** 0.85 (0.73, 0.98) * 0.71 (0.62, 0.81) ** 0.78 (0.65, 0.94) 
PDC<20% Reference Reference Reference Reference 
Adherence + Demographic variables 
   
20% ≤ PDC <40% 0.68 (0.61, 0.76) ** 0.82 (0.70, 0.97) * 0.77 (0.66, 0.89) * 0.87 (0.71, 1.07) 
40% ≤ PDC <60% 0.74 (0.66, 0.84) ** 0.91 (0.77, 1.09) 0.76 (0.65, 0.89) * 0.87 (0.70, 1.08) 
60% ≤ PDC <80% 0.68 (0.60, 0.77) ** 0.93 (0.78, 1.11) 0.80 (0.69, 0.94) * 0.88 (0.70, 1.09) 
PDC ≥80%   0.67 (0.61, 0.75) ** 0.88 (0.76, 1.02) 0.74 (0.65, 0.84) ** 0.78 (0.65, 0.94) 
PDC<20% Reference Reference Reference Reference 
Adherence + Demographic + Enrollment variables 
  
20% ≤ PDC <40% 0.70 (0.63, 0.79) ** 0.83 (0.70, 0.98) * 0.79 (0.68, 0.92) * 0.89 (0.72, 1.09) 
40% ≤ PDC <60% 0.76 (0.68, 0.86) ** 0.91 (0.77, 1.09) 0.80 (0.68, 0.93) *  0.88 (0.70, 1.09) 
60% ≤ PDC <80% 0.70 (0.61, 0.79) ** 0.94 (0.79, 1.12) 0.84 (0.72, 0.98) * 0.89 (0.71, 1.11) 
PDC ≥80%   0.70 (0.63, 0.78) ** 0.89 (0.77, 1.04) 0.78 (0.69, 0.90) * 0.80 (0.67, 0.96) 
PDC<20% Reference Reference Reference Reference 
Adherent + Demographic + Enrollment +Comorbid mental health and pain 
20% ≤ PDC <40% 0.76 (0.68, 0.85) ** 0.84 (0.71, 0.99) * 0.91 (0.79, 1.06) 0.91 (0.74, 1.11) 
40% ≤ PDC <60% 0.80 (0.70, 0.90) ** 0.93 (0.78, 1.11) 0.84 (0.72, 0.99) * 0.90 (0.72, 1.12) 
60% ≤ PDC <80% 0.79 (0.70, 0.90) ** 0.96 (0.80, 1.14) 0.95 (0.81, 1.11) 0.90 (0.72, 1.12) 
PDC ≥80%   0.77 (0.70, 0.86) ** 0.94 (0.81, 1.09) 0.90 (0.78, 1.02) 0.85 (0.71, 1.02) 
PDC<20% Reference Reference Reference Reference 
Demographic covariates = Age in years, Gender, Race (White, Black or Other), Place of residence (Urban/Rural); Enrollment covariates= Managed 
care/fee-for-service, Eligibility categories (Disabled/Chronically Ill, Expansion, Families with Children, Others); Comorbid mental health conditions 
= alcohol and substance abuse disorders, adjustment disorders, other mental health conditions; Comorbid pain conditions = back pain, neck pain, 
arthritis/joint pain, headache/migraine; MDD = Major Depressive Disorder; PDC=Proportion of days covered; Bold refers to non-violation of 
proportional hazards assumption; * = p<0.05, ** = p<0.001 
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4.4 DISCUSSION 
We sought to examine if adherence to antidepressant medications among Medicaid enrollees 
with MDD or anxiety is associated with future use of opioid medications. Our findings show that: 
i) after adjusting for demographic, enrollment, and comorbid mental illness and pain 
characteristics, enrollees with MDD and no cancer with 20% ≤ PDC <40%, 40% ≤ PDC <60%, 
60% ≤ PDC <80%, and PDC ≥80% had significantly lower hazard ratios for opioid use than 
enrollees with PDC<20%, (ii) enrollees who achieve ≥ 80% PDC were not significantly different 
with respect to opioid use than those with < 80% PDC, and (iii) with the exception of the 20% ≤ 
PDC <40% category in the MDD and cancer group, there were no significant differences in opioid 
use among enrollees with cancer and MDD or anxiety. 
Prior research has shown that unlike other chronic conditions (e.g. diabetes, hypertension), 
a large proportion of patients with MDD or anxiety often do not achieve optimal adherence (PDC 
≥ 80%) to antidepressant therapy.120-122 In this study we observed that among both MDD and 
anxiety cohorts nearly one-third of enrollees achieved PDC ≥ 80%. For both the MDD and anxiety 
cohorts with no cancer, using the dichotomous definition of adherence and examining its effects 
of on opioid use in the presence of other covariates, we did not observe any significant associations. 
However, using the multi-category definition of adherence and <20% PDC as the reference 
category, we observed that as enrollees in the 20-40%, 40-60%, 60-80%, and ≥80% adherence 
category had 24%, 20%, 21%, 23% significantly lower hazards of opioid use respectively. For the 
anxiety group with no cancer, there were 16% significantly lower hazards of opioid use for 
enrollees achieving 40-60% adherence (vs. PDC <20%). Previous research has shown that the 80% 
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PDC threshold may not reflect clinically important differences in the level of adherence.118 In this 
study, we observed that enrollees in the 20-40%, 40-60%, 60-80% PDC category also performed 
significantly better than those with <20% PDC in terms of time to first opioid use. This reflects 
that the 80% PDC threshold may not be an optimal threshold for the associations examined in this 
study. Prior research has demonstrated that differences exist in adherence to antidepressants from 
different therapeutic sub-classes.121 Also, patients with depression are heterogeneous in terms of 
their symptom experiences due to which efficacy of antidepressants may vary depending on which 
symptom clusters are being treated, in turn affecting adherence.123 The findings observed in our 
study warrant further investigations to examine variations in likelihood of opioid use based on 
antidepressant therapeutic sub-classes and depression symptom clusters.  
Our findings suggest that among patients with MDD and no cancer, adherence to 
antidepressants, may to some degree, influence the future use of opioid medications. These results, 
therefore, have potential implications for health systems such as Medicaid with an emphasis on 
using strategies to improve adherence to antidepressant medications. Recent research has shown 
that psychosocial interventions that use a personalized strategy to address barriers to adherence, 
educate patients about depression and antidepressant therapy, and encourage them to communicate 
with their provider are effective in improving adherence.124 Care models where pharmacists or 
case-managers follow up with patients at regular time-intervals to address their concerns on 
medication use have reported moderate benefit in improving adherence.125,126 Health systems 
could potentially implement plan designs that lower out-of-pocket expenditures for enrollees to 
improve adherence.  
To our knowledge, this study is the first to examine adherence to antidepressant use among 
patients with MDD and anxiety and assess its relationship on use of opioids in a large Medicaid 
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program. Other study strengths include our focus on patients initiating an anti-depressant treatment 
in the baseline period with no prior opioid use, focus on patients with and without cancer, and two 
approaches to measuring PDC thresholds. There are several limitations to our findings. First, the 
proportional hazards assumption was violated for some of the models which implies that the 
baseline hazard rates observed in this study may vary with time. Second, measuring prescription 
fills using administrative data may not represent true adherence. Third, although we adjust for 
patient level comorbidities, demographic, and enrollment variables, there are several unmeasured 
confounders that may influence adherence (e.g. patient-prescriber relationship, patient’s 
experience of using antidepressants, healthy-user bias) that cannot be accounted for given the 
nature of observational data.127,128 Fourth, limiting our analyses to only PA Medicaid claims 
reduces generalizability of our findings. Fifth, our data cannot identify events that occur outside 
of the health system. For example, patients who obtain their prescriptions from other sources such 
as safety-net programs cannot be captured. Our findings highlight the need for further research on 
this topic using prospective data that address the limitations listed above.  
4.5 CONCLUSIONS 
Taking into account the limitations of our study, we observed that enrollees with MDD and 
no cancer who achieve ≥ 20% PDC had significantly lower baseline hazard ratios for opioid use 
than enrollees with PDC<20%. The ≥ 80% PDC threshold was not optimal to measure risk of 
opioid use. With some exceptions, adherence to antidepressants among beneficiaries with cancer 
was not significantly associated with opioid use. Further studies are required to confirm our 
findings. 
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APPENDIX A: TABLES AND FIGURES FOR CHAPTER TWO 
Table A.1 Cluster evaluation indices and ratios of change 
 
Bayesian Information Criteria (BIC) 
Cluster numbers BIC Change in BIC Ratio of Change 
1 1451385.8   
2 869768.0 -581617.8  
3 687223.0 -182545.0 0.3 
4 610695.2 -76527.8 0.4 
5 534358.8 -76336.4 1.0 
6 466174.0 -68184.8 0.9 
7 424984.3 -41189.7 0.6 
8 380651.4 -44332.9 1.1 
Akaike Information Criteria (AIC) 
Cluster numbers AIC Change in AIC Ratio of Change 
1 1451294.5   
2 869585.6 -581708.9  
3 686949.3 -182636.3 0.3 
4 610330.3 -76619.0 0.4 
5 533902.6 -76427.7 1.0 
6 465626.5 -68276.1 0.9 
7 379921.5 -85705.0 1.3 
8 424345.7 44424.2 -0.5 
9 350377.3 -73968.4 -1.7 
Within Cluster Sum of Squared Errors (WCSSE) 
Cluster numbers WCSSE Change in WCSSE Ratio of Change 
1 1451276.5   
2 869549.6 -581726.9  
3 686895.3 -182654.3 0.3 
4 610258.3 -76637.0 0.4 
5 533812.6 -76445.7 1.0 
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Table A.1 continued 
6 465518.5 -68294.1 0.9 
7 424219.7 -41298.8 0.6 
8 379777.5 -44442.2 1.1 
9 350215.3 -29562.2 0.7 
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Table A.2 International Classification of Disease, 9th edition diagnosis codes for 
covariates 
 
Adjustment disorders 309.0, 309.1, 309.22,  309.23, 309.24, 309.28, 309.29, 309.3, 
309.4, 309.82, 309.83, 309.89, 309.9 
Anxiety disorders 293.84, 300.00, 300.01, 300.02, 300.09, 300.10, 300.20, 300.21, 
300.22, 300.23, 300.29, 300.3, 300.5, 300.89, 300.9, 308.0, 308.1, 
308.2, 308.3, 308.4, 308.9,  309.81, 313.0, 313.1, 313.21, 313.22, 
313.3, 313.82, 313.83 
Mood disorders 293.83, 296.00, 296.01, 296.02, 296.03, 296.04, 296.05, 296.06, 
296.10, 296.11, 296.12, 296.13, 296.14, 296.15, 296.16, 296.20, 
296.21, 296.22, 296.23, 296.24,  296.25, 296.26, 296.30, 296.31, 
296.32, 296.33, 296.34, 296.35, 296.36, 296.40, 296.41, 296.42 
296.43, 296.44, 296.45, 296.46, 296.50, 296.51, 296.52, 296.53, 
296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 
296.65, 296.66, 296.7, 296.80, 296.81, 296.82, 296.89, 296.90, 
296.99, 300.4, 311 
Personality disorders 301.0, 301.10, 301.11, 301.12, 301.13, 301.20, 301.21, 301.22, 
301.3, 301.4, 301.50, 301.51, 3015.9, 301.6, 301.7, 301.81, 
301.82, 301.83, 301.84, 301.89, 301.9 
Psychotic disorders 295 
Miscellanous  mental health 
disorders 
293.89, 293.9, 300.11, 300.12, 300.13, 300.14, 300.15, 300.16, 
300.19, 300.6, 300.7, 300.81, 300.82, 302.1, 302.2, 302.3, 302.4, 
302.50, 302.51, 302.52, 302.53, 302.6, 302.70, 302.71, 302.72, 
302.73, 302.74, 302.75, 302.76, 302.79, 302.81, 302.82, 302.83, 
302.84, 302.85, 302.89, 302.9, 306.0, 306.1, 306.2, 306.3, 306.4, 
306.50, 306.51, 306.52, 306.53, 306.59, 306.6, 306.7, 306.8, 
306.9, 307.1, 307.40, 307.41, 307.42, 307.43, 307.44, 307.45, 
307.46, 307.47, 307.48, 307.49, 307.50, 307.51, 307.52, 307.53, 
307.54, 307.59, 307.80, 307.81, 307.89, 310.1, 316, 648.40, 
648.41, 648.42, 648.43, 648.44, V40.2, V40.3, V40.31, V40.39, 
V40.9, V67.3 
Back pain 721.3, 721.4, 721.41, 721.42, 721.5, 721.6, 721.7, 721.8, 721.9, 
721.90, 721.91, 722.2, 722.30, 722.70, 722.80, 722.90, 722.32, 
722.72, 722.82, 722.92, 722.39, 722.73, 722.83, 722.93, 724.0, 
724.00, 724.01, 724.02, 724.03, 724.09, 724.1, 724.2, 724.3, 
724.4, 724.5, 724.6, 724.7, 724.70, 724.71, 724.79, 724.8, 724.9, 
737.1, 737.3, 738.4, 738.5, 756.10, 756.11, 756.12, 756.13, 
756.19, 805.4, 805.8, 839.2, 839.42, 846, 846.0, 847.1, 847.3, 
847.2, 847.9 
Neck pain 721.0, 721.1, 722.0, 722.31, 722.71, 722.81, 722.91, 723.0, 723.1, 
723.2, 723.3, 723.4, 723.5, 723.6, 723.7, 723.8, 723.9, 839.0, 
839.1, 847.0 
Arthritis/joint pain 710-710.9, 725, 726-726.91, 727-727.9, 728-728.9, 729-729.99, 
730-730.99, 731-731.8, 732-732.9, 733-733.9, 734, 735-735.9, 
736-736.9, 737-737.9, 738-738.9, 739-739.9 
Headache/ migraine  346-346.93, 307.81 
HIV/AIDS 042, 079.53, 279.10, 279.19, 795.71, 795.8, 795.81, 795.82, 
795.83 
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Patient A 
Patient B 
Patient C 
Patient D 
End of  
observation 
 
Start of  
observation with first episode  
Death  
Baseline observation period 
Episode 1 Episode 
 
Episode 
 
Episode 3 Episode 1 
Episode 1 Episode 2 
Episode 1 
Figure A.1 Establishment of Study Cohort (I) 
  71 
 
 
 
Figure A.2 Establishment of Study Cohort (II) 
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Of these, patients who PA residents, not enrolled in 
Part C and having at least one opioid claim 
(N=508,458) 
Exclude those with: 1) no opioid use (n=386,450) 
2) Death claims recorded before the opioid prescription fill claims 
(n=139) 
Of these, patients with eligible opioid use 
(N=186,799)  
Enrollees who were Pennsylvania residents and not 
enrolled in Part C (N=895,047)  
Exclude those with no continuous enrollment during baseline 
(n=34,100) 
  
Exclude those with: a) At least one diagnosis of any Metastatic 
Cancer (n=183,954), then  
b) Age <18 (n=28), then,  
c) Hospice use (n=33,882), then  
d) Long-term care (n= 69,641), then  
e) Outliers observed in pharmacy claims that were sensitive to the 
clustering process (MME/day>375) (n=54)  
Of these, patients with any opioid use (N=474,358) 
Figure A.3 Sample size flowchart from 2007-2012 
  73 
APPENDIX B: TABLES AND FIGURES FOR CHAPTER THREE 
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**Enrollees meeting any three conditions given below for each episode are considered ineligible for that episode and excluded if such ineligibility exists across all 
episodes: 
 i) date of index opioid fill < 6 months from first date of enrollment; 
 ii) date of prescription or heroin overdose < 6 month of index opioid fill;   
 iii) date of opioid use disorder < 6 months of first date of opioid 
 
 
Total beneficiaries in the Pennsylvania 
Medicaid Program, N= 5,626,740 
  
N=4,142,566 
N=434,612 
Exclude: 1) Non-Pennsylvania residents 
(n=213,021), then 
             2) Dual eligible (n=846,378), then 
3) Any cancer diagnosis 
(n=424,775) 
  
Exclude:1) No opioid use (n=3,295,954), 
then 
2) Baseline ineligibility for each 
episode and across all episodes 
(n=213,806)**, then 
3) Baseline methadone or 
buprenorphine use (n=1,382) 
  
Exclude: 1) Age <18 or age >64 years old 
(n=194,485), then  
2) Long-term care ≥90 days 
(n=2,259), then 
3) Receiving hospice benefits 
(n=68) 
N=631,424 
Figure B.1 Cohort Selection Flow Chart, Pennsylvania Medicaid: 2007-2015 
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Table B.1 International Classification of Disease, 9th and 10th edition for opioid-use disorder and overdose 
 
 Opioid use disorder  
ICD-9 304.0, 304.00, 304.01, 304.02, 304.03, 304.7, 304.70, 304.71, 
304.72, 304.73, 305.5, 305.50, 305.51, 305.52, 305.53 
ICD-10 F1110, F11120, F11121, F11122, F11129, F1114, F11150, 
F11151, F11159, F11181, F11182, F11188, F1119, F1120, F1121, 
F11220, F11221, F11222, F11229, F1123, F1124, F11250, 
F11251, F11259, F11281, F11282, F11288, F1129, F1190, 
F11920, F11921, F11922, F11929, F1193, F1194, F11950, 
F11951, F11959, F11981, F11982, F11988, F1199 
Overdose 
ICD-9 965.00,965.02, 965.09, E.850.1, E.850.2 
ICD-10 T401X, T401X1, T401X1A, T401X1D, T401X1S, T401X3, 
T401X3A, T401X3D, T401X3S, T401X4, T401X4A, T401X4D, 
T401X4S, T400X1A, T400X3A, T400X4A, T402X1A, T402X1D 
T402X1S, T402X3A, T402X3D, T402X3S, T402X4A, T402X4D, 
T402X4S, T402X5A, T402X5D T402X5S, T403X1, T403X1A, 
T403X1D, T403X1S, T403X3A, T403X3D, T403X3S, T403X4A 
T403X4D, T403X4S, T403X5A, T403X5D, T403X5S, T404X1, 
T404X1A, T404X1D, T404X1S T404X3A, T404X3D, T404X3S, 
T404X4A, T404X4D, T404X4S, T404X5A, T404X5D, T404X5S 
T40601A, T40603A, T40604A, T40691, T40691A, T40693A, 
T40694A. 
ICD-9: International Classification of Diseases, 9th Revision  
ICD-10: International Classification of Diseases, 10th Revision 
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Table B.2 Associations between prescribing specialty and opioid use disorder showing the adjusted rates for all covariates 
including prescribing specialty, demographic and enrollment variables, comorbid conditions, and use of other health services 
 
 Index prescriber Dominant prescriber 
Parameters Adjusted Rates P Adjusted Rates P 
Dentistry  0.86 [0.82, 0.90] <.0001 0.83 [0.80, 0.87] <.0001 
Emergency Medicine 1.02 [0.97, 1.07] 0.48 1.00 [0.96, 1.05] 0.91 
Obstetrics/Gynecology 0.63 [0.59, 0.68] <.0001 0.55 [0.51, 0.59] <.0001 
Pain medicine/Anesthesiology 1.53 [1.25, 1.88] <.0001 1.31 [1.13, 1.52] 0.0004 
Physical Medicine and Rehabilitation 1.33 [1.13, 1.57] 0.0006 1.20 [1.06, 1.36] 0.0031 
Podiatry 0.75 [0.60, 0.94] 0.01 0.81 [0.68, 0.97] 0.02 
Psychiatry 1.08 [0.90, 1.30] 0.41 1.16 [0.98, 1.38] 0.09 
Surgery 0.74 [0.69, 0.80] <.0001 0.76 [0.71, 0.81] <.0001 
Other 0.86 [0.79, 0.94] 0.0005 0.89 [0.82, 0.96] 0.0026 
Combination of other specialtiesa N/A  0.84 [0.77, 0.91] <.0001 
Combination of primary care and other 
specialtyb 
N/A  1.01 [0.94, 1.08] 0.77 
Primary Care Reference  Reference  
Demographics 
    
Female 0.60 [0.58, 0.62] <.0001 0.61 [0.59, 0.63] <.0001 
Age at first episode, years 0.99 [0.99, 1.00] <.0001 0.99 [0.99, 0.99] <.0001 
White 2.41 [2.31, 2.52] <.0001 2.34 [2.25, 2.42] <.0001 
MCO 2.15 [1.95, 2.36] <.0001 2.15 [1.97, 2.35] <.0001 
Urban 1.16 [1.11, 1.21] <.0001 1.16 [1.12, 1.21] <.0001 
Eligibility Category (reference = 
Families with Children)  
    
Disabled/Chronically Ill 1.44 [1.38, 1.50] <.0001 1.44 [1.39, 1.50] <.0001 
Expansion 3.02 [2.75, 3.32] <.0001 3.10 [2.85, 3.36] <.0001 
Other 1.58 [1.48, 1.69] <.0001 1.57 [1.48, 1.66] <.0001 
MME/day (reference <20)     
20-49.9 0.93 [0.88, 0.97] 0.0008 0.97 [0.94, 1.01] 0.17 
50-99.9 0.97 [0.92, 1.03] 0.29 0.98 [0.93, 1.03] 0.37 
≥100 1.12 [1.02, 1.22] 0.02 1.44 [1.34, 1.54] <.0001 
Comorbid conditionsc     
Alcohol abuse/dependence 1.15 [1.08, 1.23] <.0001 1.13 [1.07, 1.20] <.0001 
Non-opioid drug abuse/dependence 3.11 [2.97, 3.26] <.0001 2.98 [2.85, 3.10] <.0001 
Adjustment disorders 0.81 [0.73, 0.90] 0.0001 0.83 [0.76, 0.92] 0.0001 
Anxiety disorders 1.18 [1.13, 1.24] <.0001 1.18 [1.13, 1.23] <.0001 
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Table B.2 Continued 
Mood disorders 1.27 [1.22, 1.32] <.0001 1.27 [1.22, 1.32] <.0001 
Miscellaneous mental health disorders 1.14 [1.05, 1.23] 0.0012 1.12 [1.04, 1.20] 0.0028 
Back pain 1.20 [1.15, 1.26] <.0001 1.19 [1.14, 1.23] <.0001 
Neck pain 0.94 [0.88, 1.01] 0.11 0.94 [0.88, 1.00] 0.04 
HIV/AIDS 1.53 [1.31, 1.78] <.0001 1.50 [1.31, 1.72] <.0001 
Arthritis/joint pain 0.92 [0.87, 0.96] 0.0002 0.91 [0.88, 0.95] <.0001 
Headache/migraine pain 0.91 [0.83, 0.99] 0.04 0.92 [0.84, 0.99] 0.04 
Use of health servicesd 
    
Emergency Department visit 1.21 [1.16, 1.25] <.0001 1.23 [1.19, 1.27] <.0001 
Buprenorphine Use 6.58 [6.15, 7.05] <.0001 6.21 [5.84, 6.60] <.0001 
Benzodiazepine Use 1.44 [1.37, 1.51] <.0001 1.41 [1.36, 1.48] <.0001 
Muscle Relaxant use 1.02 [0.95, 1.10] 0.54 1.03 [0.97, 1.09] 0.39 
Elixhauser Index 0.88 [0.87, 0.90] <.0001 0.89 [0.87, 0.90] <.0001 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying length 
of exposure to opioid treatment; AIDS= Acquired immune deficiency syndrome, MCO= Managed care organization, MME= Morphine 
milligram equivalents; a Refers to episodes where more than one non-primary care specialty has equal prescription claims; bRefers to episodes 
where prescription claims from primary care and other non- primary care specialty are equal;  c,d The comorbid conditions, Elixhauser index, and 
use of benzodiazepines and muscle relaxants, and emergency department visits were measured during the six-month baseline period.  
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Table B.3 Adjusted rates for associations between prescribing specialty and misuse showing the adjusted rates for all 
covariates including prescribing specialty, demographic and enrollment variables, comorbid conditions, and use of other 
health services 
 
 Index prescriber Dominant prescriber 
Parameters Adjusted Rates P Adjusted Rates P 
Dentistry  0.39 [0.36, 0.41] <.0001 0.26 [0.25, 0.28] <.0001 
Emergency Medicine 0.78 [0.74, 0.82] <.0001 0.41 [0.39, 0.43] <.0001 
Obstetrics/Gynecology 0.46 [0.42, 0.50] <.0001 0.15 [0.13, 0.17] <.0001 
Pain Medicine/Anesthesiology 1.62 [1.36, 1.92] <.0001 1.86 [1.68, 2.07] <.0001 
Physical Medicine and Rehabilitation 1.61 [1.41, 1.84] <.0001 1.66 [1.51, 1.81] <.0001 
Podiatry 0.76 [0.62, 0.93] 0.01 0.97 [0.85, 1.11] 0.69 
Psychiatry 1.00 [0.81, 1.24] 0.99 0.76 [0.61, 0.94] 0.01 
Surgery 0.66 [0.61, 0.71] <.0001 0.67 [0.63, 0.71] <.0001 
Other 0.79 [0.72, 0.86] <.0001 0.62 [0.57, 0.67] <.0001 
Combination of other specialties a N/A  0.43 [0.39, 0.48] <.0001 
Combination of primary care and other 
specialty b 
N/A  0.78 [0.73, 0.83] <.0001 
Primary Care Reference 
 
 
 
Demographics     
Female 0.78 [0.75, 0.82] <.0001 0.83 [0.80, 0.86] <.0001 
Age at first episode, years 1.02 [1.01, 1.02] <.0001 1.01 [1.01, 1.01] <.0001 
White 1.45 [1.39, 1.52] <.0001 1.35 [1.30, 1.40] <.0001 
MCO 1.34 [1.23, 1.46] <.0001 1.13 [1.09, 1.17] <.0001 
Urban 1.12 [1.07, 1.18] <.0001 1.14 [1.09, 1.19] <.0001 
Eligibility Category (reference = 
Families with Children) 
    
Disabled/Chronically Ill 1.38 [1.32,1.45] <.0001 1.37 [1.31, 1.43] <.0001 
Expansion 3.11 [2.80,3.44] <.0001 2.90 [2.64, 3.18] <.0001 
Other 1.51 [1.41,1.63] <.0001 1.49 [1.40, 1.58] <.0001 
MME/day (reference <20) 
    
20-49.9 0.94 [0.90, 0.99] 0.02 1.31 [1.26, 1.37] <.0001 
50-99.9 0.96 [0.90, 1.03] 0.24 1.22 [1.16, 1.29] <.0001 
≥100 1.29 [1.17, 1.41] <.0001 2.07 [1.93, 2.22] <.0001 
Comorbid conditions c 
    
Alcohol abuse/dependence 1.15 [1.06, 1.25] 0.001 1.12 [1.05, 1.20] 0.002 
Non-opioid drug abuse/dependence 1.28 [1.20, 1.37] <.0001 1.26 [1.19, 1.34] <.0001 
Adjustment disorders 0.96 [0.86, 1.08] 0.50 0.98 [0.89, 1.09] 0.73 
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Table B.3 continued 
Anxiety disorders 1.13 [1.07, 1.20] <.0001 1.12 [1.07, 1.18] <.0001 
Mood disorders 1.13 [1.08, 1.18] <.0001 1.10 [1.06, 1.15] <.0001 
Miscellaneous mental health disorders 1.15 [1.04, 1.26] 0.0039 1.15 [1.06, 1.25] 0.007 
Back pain 1.57 [1.50, 1.64] <.0001 1.43 [1.38, 1.49] <.0001 
Neck pain 1.01 [0.94, 1.08] 0.87 1.01 [0.95, 1.07] 0.86 
HIV/AIDS 1.16 [0.96, 1.38] 0.12 1.07 [0.91, 1.25] 0.43 
Arthritis/joint pain 1.12 [1.07, 1.17] <.0001 1.06 [1.02, 1.11] 0.002 
Headache/migraine pain 1.26 [1.15, 1.37] <.0001 1.18 [1.10, 1.28] <.0001 
Use of health services d 
 
  
  
Baseline ED visit 1.27 [1.22, 1.33] <.0001 1.37 [1.32, 1.42] <.0001 
Buprenorphine Use 1.82 [1.69, 1.96] <.0001 1.66 [1.56, 1.77] <.0001 
Baseline Benzodiazepine Use 1.37 [1.30, 1.45] <.0001 1.30 [1.25, 1.37] <.0001 
Baseline Muscle Relaxant use 1.15 [1.08, 1.23] <.0001 1.14 [1.08, 1.20] <.0001 
Elixhauser Index 0.97 [0.95, 0.99] 0.001 0.96 [0.95, 0.98] <.0001 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying length of 
exposure to opioid treatment; AIDS= Acquired immune deficiency syndrome, MCO= Managed care organization, MME= Morphine milligram 
equivalents; a Refers to episodes where more than one non-primary care specialty has equal prescription claims; bRefers to episodes where 
prescription claims from primary care and other non- primary care specialty are equal;  c,d The comorbid conditions, Elixhauser index, and use of 
benzodiazepines and muscle relaxants, and emergency department visits were measured during the six-month baseline period. 
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Table B.4 Adjusted rates for associations between prescribing specialty and overdose showing the adjusted rates for all 
covariates including prescribing specialty, demographic and enrollment variables, comorbid conditions, and use of other 
health services 
 
  Index prescriber Dominant prescriber 
Parameters Adjusted Rates P Adjusted Rates P 
Dentistry  0.66 [0.53, 0.82] 0.0002 0.59 [0.48, 0.73] <.0001 
Emergency Medicine 0.74 [0.59, 0.91] 0.0049 0.62 [0.50, 0.77] <.0001 
Obstetrics/Gynecology 0.37 [0.25, 0.55] <.0001 0.31 [0.20, 0.47] <.0001 
Pain medicine/Anesthesiology 2.12 [1.08, 4.14] 0.03 1.04 [0.57, 1.90] 0.90 
Physical Medicine and Rehabilitation 1.84 [1.07, 3.19] 0.03 1.31 [0.84, 2.05] 0.23 
Podiatry 0.94 [0.38, 2.29] 0.89 0.63 [0.28, 1.42] 0.26 
Psychiatry 1.48 [0.76, 2.89] 0.25 1.19 [0.59, 2.40] 0.63 
Surgery 0.64 [0.45, 0.90] 0.01 0.59 [0.44, 0.80] 0.001 
Other 1.16 [0.84, 1.61] 0.36 0.85 [0.61, 1.19] 0.35 
Combination of other specialtiesa N/A  0.70 [0.48, 1.02] 0.06 
Combination of primary care and other 
specialtyb 
N/A  0.93 [0.69, 1.25] 0.64 
Primary Care Reference  Reference  
Demographics 
    
Female 0.67 [0.56, 0.79] <.0001 0.66 [0.57, 0.77] <.0001 
Age at first episode, years 1.00 [0.99, 1.00] 0.27 0.99 [0.99, 1.00] 0.13 
White 2.39 [1.96, 2.91] <.0001 2.24 [1.88, 2.66] <.0001 
MCO 1.49 [1.03, 2.14] 0.03 1.52 [1.07, 2.15] 0.02 
Urban 1.18 [0.97, 1.44] 0.10 1.19 [0.99, 1.43] 0.07 
Eligibility Category (reference = 
Families with Children) 
    
Disabled/Chronically Ill 1.32 [1.09, 1.61] 0.01 1.36 [1.14, 1.62] 0.0005 
Expansion 2.26 [1.39, 3.67] 0.001 2.42 [1.59, 3.69] <.0001 
Other 1.86 [1.43, 2.44] <.0001 1.76 [1.38, 2.25] <.0001 
MME/day (reference <20)   1.36 [1.14, 1.62] 0.0005 
20-49.9 0.94 [0.76, 1.16] 0.54 1.12 [0.94, 1.35] 0.21 
50-99.9 1.19 [0.92, 1.53] 0.19 1.34 [1.06, 1.68] 0.01 
≥100 1.67 [1.18, 2.39] 0.0043 2.21 [1.65, 2.95] <.0001 
Comorbid conditionsc     
Alcohol abuse/dependence 1.60 [1.22, 2.10] 0.0007 1.61 [1.26, 2.05] 0.0001 
Non-opioid drug abuse/dependence 2.00 [1.58, 2.52] <.0001 2.00 [1.63, 2.46] <.0001 
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Table B.4 continued 
Adjustment disorders 1.44 [1.00, 2.06] 0.05 1.33 [0.95, 1.87] 0.10 
Anxiety disorders 1.26 [1.02, 1.55] 0.03 1.34 [1.12, 1.62] 0.0018 
Mood disorders 1.42 [1.18, 1.71] 0.0002 1.32 [1.12, 1.55] 0.0011 
Miscellaneous mental health disorders 0.67 [0.43, 1.06] 0.09 0.66 [0.44, 0.99] 0.05 
Back pain 1.64 [1.36, 1.99] <.0001 1.52 [1.29, 1.80] <.0001 
Neck pain 1.03 [0.77, 1.37] 0.87 1.06 [0.83, 1.36] 0.64 
HIV/AIDS 0.85 [0.35, 2.07] 0.73 0.90 [0.43, 1.91] 0.79 
Arthritis/joint pain 0.88 [0.72, 1.08] 0.21 0.93 [0.78, 1.11] 0.44 
Headache/migraine pain 0.83 [0.54, 1.27] 0.39 0.85 [0.59, 1.23] 0.39 
Use of health servicesd 
    
Emergency Department visit 1.43[1.20, 1.71] <.0001 1.42 [1.21, 1.65] <.0001 
Buprenorphine Use 1.61[1.22, 2.12] 0.0007 1.53 [1.20, 1.96] 0.0006 
Benzodiazepine Use 1.69[1.38, 2.08] <.0001 1.61 [1.34, 1.93] <.0001 
Muscle Relaxant use 0.99[0.74, 1.32] 0.93 1.15 [0.90, 1.46] 0.25 
Elixhauser Index 0.98[0.92, 1.06] 0.64 0.98 [0.92, 1.05] 0.57 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying length 
of exposure to opioid treatment; AIDS= Acquired immune deficiency syndrome, ARR = Adjusted Rate Ratio, MCO= Managed care 
organization, MME= Morphine milligram equivalents; a Refers to episodes where more than one non-primary care specialty has equal 
prescription claims; bRefers to episodes where prescription claims from primary care and other non- primary care specialty are equal;  c,d The 
comorbid conditions, Elixhauser index, and use of benzodiazepines and muscle relaxants, and emergency department visits were measured 
during the six-month baseline period.  
 
 
 
 
 
 
 
  82 
 
 
Table B.5 Distribution of prescriber specialties for index opioid prescription– results from imputed datasets 
 
 
 
 
 
 
 
 
 
 
       Imputation 1      Imputation 2 Imputation 3      Imputation 4      Imputation 5 
Dentistry 116910 26.9 116709 26.85 116851 26.89 116619 26.83 116868 26.89 
Emergency Medicine 87217 20.07 87307 20.09 87251 20.08 87134 20.05 87158 20.05 
Obstetrics/Gynecology 46602 10.72 46519 10.7 46596 10.72 46659 10.74 46532 10.71 
Pain Medicine/Anesthesiology 2834 0.65 2866 0.66 2805 0.65 2885 0.66 2854 0.66 
Physical Medicine and 
Rehabilitation 
4232 0.97 4253 0.98 4295 0.99 4347 1.00 4278 0.98 
Primary Care 121727 28.01 121863 28.04 121699 28.00 121645 27.99 121746 28.01 
Podiatry 4097 0.94 4057 0.93 4048 0.93 4069 0.94 4049 0.93 
Psychiatry 1692 0.39 1672 0.38 1649 0.38 1659 0.38 1738 0.4 
Surgery 28859 6.64 28857 6.64 28884 6.65 29043 6.68 28840 6.64 
Others 20442 4.7 20509 4.72 20534 4.72 20552 4.73 20549 4.73 
  83 
 
Table B.6 Distribution of dominant provider specialties in an episode – results from imputed datasets 
  
Imputation 1 Imputation 2 Imputation 3 Imputation 4  Imputation 5 
Dentistry 105944 24.38 105757 24.33 105968 24.38 105688 24.32 105955 24.38 
Emergency Medicine 65775 15.13 65873 15.16 65742 15.13 65712 15.12 65727 15.12 
Obstetrics/Gynecology 58486 13.46 58477 13.45 58515 13.46 58625 13.49 58528 13.47 
Pain Medicine/Anesthesiology 2180 0.5 2243 0.52 2204 0.51 2205 0.51 2130 0.49 
Primary Care 110559 25.43 110515 25.43 110541 25.44 110491 25.4 110347 25.4 
Physical Medicine and 
Rehabilitation 
3304 0.76 3268 0.75 3302 0.76 3325 0.77 3350 0.77 
Podiatry 3561 0.82 3564 0.82 3563 0.82 3555 0.82 3511 0.81 
Psychiatry 1248 0.29 1237 0.28 1185 0.27 1239 0.29 1275 0.29 
Other 15941 3.67 16059 3.7 16107 3.71 16031 3.69 16015 3.68 
Surgery 25194 5.8 25198 5.8 25135 5.78 25326 5.83 25213 5.8 
Combination of other specialties a 16323 3.76 16291 3.75 16342 3.76 16285 3.75 16350 3.76 
Combination of primary care and 
other specialty b 
26097 6.0 26130 6.01 26008 5.98 26130 6.01 26211 6.03 
a Refers to episodes where more than one non-primary care specialty has equal prescription claims; b Refers to episodes where prescription claims from primary 
care and other non- primary care specialty are equal 
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Table B.7 Adjusted rates for associations between prescribing specialty and opioid use disorder – results from imputed models 
 
 Index prescriber Dominant prescriber 
Parameters Adjusted Rates P Adjusted Rates P 
Dentistry  0.91 [0.83, 0.99] 0.03 0.85 [0.81, 0.90] <.0001 
Emergency Medicine 0.94 [0.85, 1.03] 0.19 1.00 [0.95, 1.05] 0.88 
Obstetrics/Gynecology 0.68 [0.57, 0.80] <.0001 0.83 [0.78, 0.88] <.0001 
Pain medicine/Anesthesiology 1.54 [1.20, 1.97] 0.0007 1.38 [1.19, 1.60] <.0001 
Physical Medicine and 
Rehabilitation 
1.25 [1.00, 1.57] 0.05 1.16 [1.01, 1.33] 0.03 
Podiatry 0.95 [0.69, 1.31] 0.76 0.85 [0.71, 1.01] 0.07 
Psychiatry 1.31 [0.91, 1.88] 0.14 1.17 [0.97, 1.42] 0.10 
Surgery 0.80 [0.68, 0.94] 0.01 0.75 [0.70, 0.80] <.0001 
Other 0.96 [0.82, 1.11] 0.56 0.88 [0.80, 0.96] 0.003 
Combination of other specialtiesa N/A  0.90 [0.83, 0.98] 0.01 
 Combination of primary care and 
other specialtyb 
N/A  1.04 [0.98, 1.11] 0.16 
Primary Care Reference  Reference  
Demographics 
    
Female 0.63 [0.59, 0.67] <.0001 0.59 [0.58, 0.61] <.0001 
Age at first episode, years 0.99 [0.99, 1.00] <.0001 0.99 [0.99, 1.00] <.0001 
White 1.88 [1.76, 2.01] <.0001 2.43 [2.35, 2.52] <.0001 
MCO 1.02 [0.89, 1.18] 0.76 2.15 [1.97, 2.34] <.0001 
Urban 1.37 [1.24, 1.50] <.0001 1.14 [1.10, 1.19] <.0001 
Eligibility Category (reference = 
Families with Children) 
    
Disabled/Chronically Ill 1.65 [1.53, 1.78] <.0001 1.50 [1.45, 1.55] <.0001 
Expansion 3.72 [3.10, 4.46] <.0001 3.21 [2.98, 3.45] <.0001 
Other 1.90 [1.69, 2.14] <.0001 1.56 [1.48, 1.65] <.0001 
MME/day (reference <20)     
20-49.9 0.98 [0.90, 1.06] 0.59 0.96 [0.92, 0.99] 0.02 
50-99.9 0.97 [0.87, 1.08] 0.54 0.93 [0.89, 0.98] 0.003 
≥100 1.13 [0.96, 1.34] 0.14 1.41 [1.32, 1.51] <.0001 
Comorbid conditionsc     
Alcohol abuse/dependence 1.07 [0.96, 1.19] 0.22 1.12 [1.06, 1.18] <.0001 
Non-opioid drug abuse/dependence 3.30 [3.05, 3.58] <.0001 3.10 [2.99, 3.22] <.0001 
Adjustment disorders 0.85 [0.70, 1.04] 0.11 0.84 [0.77, 0.91] <.0001 
Anxiety disorders 1.11 [1.02, 1.21] 0.02 1.17 [1.13, 1.22] <.0001 
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Table B.7 continued 
Mood disorders 1.26 [1.17, 1.35] <.0001 1.28 [1.24, 1.33] <.0001 
Miscellaneous mental health 
disorders 
1.26 [1.08, 1.46] 0.003 1.08 [1.01, 1.15] 0.03 
Back pain 1.14 [1.05, 1.24] 0.002 1.19 [1.14, 1.23] <.0001 
Neck pain 0.91 [0.80, 1.03] 0.14 0.93 [0.88, 0.99] 0.02 
HIV/AIDS 1.55 [1.26, 1.90] <.0001 1.53 [1.35, 1.72] <.0001 
Arthritis/joint pain 0.96 [0.88, 1.04] 0.27 0.92 [0.89, 0.96] <.0001 
Headache/migraine pain 0.97 [0.82, 1.15] 0.73 0.91 [0.84, 0.98] 0.02 
Use of health services d 
    
Emergency Department visit 1.23 [1.14, 1.32] <.0001 1.26 [1.22, 1.30] <.0001 
Buprenorphine Use 6.31 [5.53, 7.19] <.0001 6.34 [5.99, 6.72] <.0001 
Benzodiazepine Use 1.46 [1.35, 1.59] <.0001 1.45 [1.40, 1.51] <.0001 
Muscle Relaxant use 1.02 [0.91, 1.15] 0.72 1.05 [0.99, 1.11] 0.12 
Elixhauser Index 0.89 [0.87, 0.92] <.0001 0.89 [0.87, 0.90] <.0001 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying length 
of exposure to opioid treatment; AIDS= Acquired immune deficiency syndrome, MCO= Managed care organization, MME= Morphine 
milligram equivalents; a Refers to episodes where more than one non-primary care specialty has equal prescription claims; bRefers to episodes 
where prescription claims from primary care and other non- primary care specialty are equal;  c,d The comorbid conditions, Elixhauser index, 
and use of benzodiazepines and muscle relaxants, and emergency department visits were measured during the six-month baseline period.  
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Table B.8 Adjusted rates for associations between prescribing specialty and misuse - results from imputed models 
 
 Index prescriber Dominant prescriber 
Parameter Adjusted Rates P Adjusted Rates P 
Dentistry  0.38 [0.33, 0.43] <.0001 0.22 [0.21, 0.24] <.0001 
Emergency Medicine 0.69 [0.63, 0.76] <.0001 0.34 [0.32, 0.36] <.0001 
Obstetrics/Gynecology 0.37 [0.31, 0.45] <.0001 1.19 [1.14, 1.25] <.0001 
Pain Medicine/Anesthesiology 1.48 [1.10, 1.98] 0.01 1.79 [1.59, 2.01] <.0001 
Physical Medicine and 
Rehabilitation 
1.54 [1.24, 1.92] 0.0001 1.49 [1.34, 1.65] <.0001 
Podiatry 1.06 [0.77, 1.47] 0.71 0.91 [0.78, 1.05] 0.20 
Psychiatry 1.42 [1.02, 1.97] 0.04 0.63 [0.50, 0.81] 0.00 
Surgery 0.69 [0.60, 0.80] <.0001 0.60 [0.56, 0.65] <.0001 
Other 0.80 [0.67, 0.95] 0.01 0.55 [0.51, 0.61] <.0001 
Combination of other specialties a N/A  0.24 [0.20, 0.28] <.0001 
Combination of primary care and 
other specialty b 
N/A  0.47 [0.43, 0.51] <.0001 
Primary Care Reference    
Demographics 
   
Female 0.81 [0.76, 0.87] <.0001 0.69 [0.66, 0.71] <.0001 
Age at first episode, years 1.01 [1.00, 1.01] 0.01 1.01 [1.01, 1.02] <.0001 
White 1.18 [1.10, 1.26] <.0001 1.37 [1.32, 1.42] <.0001 
MCO 1.03 [0.78, 1.34] 0.84 1.47 [1.36, 1.58] <.0001 
Urban 1.32 [1.19, 1.45] <.0001 1.15 [1.11, 1.20] <.0001 
Eligibility Category (reference = Families with Children) 
Disabled/Chronically Ill 1.54 [1.41, 1.67] <.0001 1.51 [1.45, 1.57] <.0001 
Expansion 3.65 [2.99, 4.45] <.0001 3.17 [2.90, 3.47] <.0001 
Other 1.77 [1.56, 2.01] <.0001 1.65 [1.56, 1.75] <.0001 
MME/day (reference <20) 
  
20-49.9 0.97 [0.89, 1.06] 0.55 1.25 [1.20, 1.30] <.0001 
50-99.9 1.01 [0.90, 1.12] 0.90 1.10 [1.05, 1.16] 0.0002 
≥100 1.30 [1.11, 1.52] 0.0014 2.04 [1.91, 2.17] <.0001 
Comorbid conditions c 
   
Alcohol abuse/dependence 0.95 [0.83, 1.10] 0.51 1.11 [1.04, 1.19] 0.0014 
Non-opioid drug abuse/dependence 1.26 [1.13, 1.41] <.0001 1.26 [1.19, 1.33] <.0001 
Adjustment disorders 0.89 [0.71, 1.11] 0.29 1.01 [0.92, 1.11] 0.84 
Anxiety disorders 1.13 [1.03, 1.25] 0.01 1.14 [1.09, 1.20] <.0001 
Mood disorders 1.08 [0.99, 1.17] 0.07 1.13 [1.08, 1.17] <.0001 
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Table B.8 continued 
Miscellaneous mental health 
disorders 
1.05 [0.88, 1.26] 0.59 0.87 [0.81, 0.95] 0.0007 
Back pain 1.46 [1.35, 1.58] <.0001 1.46 [1.41, 1.52] <.0001 
Neck pain 1.01 [0.90, 1.14] 0.84 1.04 [0.98, 1.10] 0.17 
HIV/AIDS 1.20 [0.94, 1.54] 0.14 1.09 [0.93, 1.26] 0.28 
Arthritis/joint pain 1.13 [1.04, 1.22] 0.003 1.11 [1.07, 1.16] <.0001 
Headache/migraine pain 1.19 [1.02, 1.39] 0.03 1.27 [1.19, 1.37] <.0001 
Use of health services d 
   
Emergency Department visit 1.18 [1.10, 1.28] <.0001 1.51 [1.46, 1.56] <.0001 
Buprenorphine Use 1.72 [1.50, 1.97] <.0001 1.78 [1.68, 1.88] <.0001 
Benzodiazepine Use 1.34 [1.23, 1.47] <.0001 1.34 [1.28, 1.40] <.0001 
Muscle Relaxant use 1.25 [1.12, 1.39] <.0001 1.16 [1.10, 1.22] <.0001 
Elixhauser Index 0.98 [0.95, 1.00] 0.10 0.95 [0.93, 0.96] <.0001 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying length 
of exposure to opioid treatment; AIDS= Acquired immune deficiency syndrome, MCO= Managed care organization, MME= Morphine 
milligram equivalents; a Refers to episodes where more than one non-primary care specialty has equal prescription claims; b Refers to episodes 
where prescription claims from primary care and other non- primary care specialty are equal;  c,d The comorbid conditions, Elixhauser index, 
and use of benzodiazepines and muscle relaxants, and emergency department visits were measured during the six-month baseline period. 
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Table B.9 Adjusted rates for associations between prescribing specialty and overdose - results from imputed models 
 
 Index prescriber  Dominant prescriber 
Parameter Adjusted Rates P Adjusted Rates P 
Dentistry 0.66 [0.40, 1.10] 0.11 0.58 [0.47, 0.71] <.0001 
Emergency Medicine 0.83 [0.55, 1.27] 0.39 0.64 [0.51, 0.79] <.0001 
Obstetrics/Gynecology 0.11 [0.01, 1.11] 0.06 0.60 [0.46, 0.78] 0.0001 
Pain Medicine/Anesthesiology 2.49 [1.05, 5.87] 0.04 1.01 [0.52, 1.96] 0.98 
Physical Medicine and Rehabilitation 0.62 [0.13, 2.85] 0.52 1.13 [0.71, 1.78] 0.61 
Podiatry 0.91 [0.22, 3.85] 0.90 0.46 [0.17, 1.21] 0.12 
Psychiatry 1.79 [0.60, 5.36] 0.29 0.89 [0.37, 2.13] 0.79 
Surgery 0.42 [0.17, 1.04] 0.06 0.52 [0.35, 0.76] 0.001 
Other  1.19 [0.55, 2.61] 0.65 0.84 [0.58, 1.24] 0.38 
Combination of other specialties b N/A  0.65 [0.43, 0.99] 0.05 
Combination of primary care and other 
specialtya 
N/A  0.77 [0.54, 1.11] 0.16 
Primary Care Reference  Reference  
Demographics  
Female 0.72 [0.54, 0.98] 0.03 0.66 [0.57, 0.75] <.0001 
Age at first episode, years 1.00 [0.98, 1.01] 0.65 1.00 [0.99, 1.00] 0.17 
White 3.09 [2.19, 4.38] <.0001 2.27 [1.94, 2.67] <.0001 
MCO 0.99 [0.43, 2.29] 0.98 1.46 [1.05, 2.04] 0.03 
Urban 1.05 [0.72, 1.53] 0.80 1.14 [0.95, 1.35] 0.15 
Eligibility Category (reference = Families with Children) 
Disabled/Chronically Ill 1.41 [0.99, 2.01] 0.06 1.38 [1.18, 1.63] <.0001 
Expansion 2.20 [0.79, 6.12] 0.13 2.60 [1.78, 3.80] <.0001 
Other 2.16 [1.32, 3.53] 0.002 1.74 [1.38, 2.19] <.0001 
MME/day (reference <20) 
20-49.9 1.23 [0.81, 1.86] 0.33 1.07 [0.90, 1.26] 0.45 
50-99.9 1.58 [0.96, 2.58] 0.07 1.28 [1.03, 1.58] 0.02 
≥100 2.67 [1.44, 4.93] 0.0018 2.15 [1.64, 2.83] <.0001 
Comorbid conditions c  
Alcohol abuse/dependence 1.74 [1.12, 2.72] 0.01 1.52 [1.21, 1.91] 0.0004 
Non-opioid drug abuse/dependence 2.25 [1.52, 3.32] <.0001 2.07 [1.70, 2.51] <.0001 
Adjustment disorders 0.69 [0.28, 1.69] 0.41 1.26 [0.91, 1.74] 0.17 
Anxiety disorders 1.35 [0.93, 1.94] 0.11 1.36 [1.14, 1.62] 0.0006 
Mood disorders 1.44 [1.04, 2.00] 0.03 1.33 [1.14, 1.56] 0.0003 
Miscellaneous mental health disorders 1.01 [0.47, 2.17] 0.98 0.65 [0.44, 0.95] 0.03 
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Table B.9 continued 
Back pain 1.34 [0.95, 1.89] 0.10 1.50 [1.28, 1.76] <.0001 
Neck pain 0.98 [0.59, 1.63] 0.94 1.10 [0.87, 1.40] 0.41 
HIV/AIDS 0.36 [0.05, 2.62] 0.32 0.77 [0.36, 1.62] 0.49 
Arthritis/joint pain 0.87 [0.61, 1.25] 0.46 1.01 [0.86, 1.19] 0.90 
Headache/migraine pain 0.44 [0.16, 1.20] 0.11 0.84 [0.59, 1.20] 0.34 
Use of health services d 
  
Emergency Department visit 1.30 [0.93, 1.81] 0.13 1.37 [1.18, 1.58] <.0001 
Buprenorphine Use 1.83 [1.13, 2.96] 0.01 1.62 [1.28, 2.04] <.0001 
Benzodiazepine Use 1.70 [1.20, 2.41] 0.0029 1.68 [1.41, 1.99] <.0001 
Muscle Relaxant use 2.12 [1.42, 3.16] 0.003 1.22 [0.97, 1.52] 0.09 
Elixhauser Index 1.00 [0.90, 1.13] 0.94 0.98 [0.93, 1.04] 0.55 
Poisson distribution with log link function is used; Model is offset using the natural log of the days of follow-up to account for varying length of 
exposure to opioid treatment; AIDS= Acquired immune deficiency syndrome, MCO= Managed care organization, MME= Morphine milligram 
equivalents; a Refers to episodes where more than one non-primary care specialty has equal prescription claims; b Refers to episodes where 
prescription claims from primary care and other non- primary care specialty are equal;  c,d The comorbid conditions, Elixhauser index, and use of 
benzodiazepines and muscle relaxants, and emergency department visits were measured during the six-month baseline period. 
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Note: i) Baseline period and adherence measurement period require continuous enrollment for at least 15 
days for six consecutive months, ii) The blue-colored bar represents the adherence measurement period of 
180 days. Enrollees with any opioid use during this period were excluded. The red-colored region represents 
period during which opioid use was measured  
 
Opioid Use 
  
INDEX 
EVENT 
ADHERENCE 
MEASUREMENT 
(Duration = 180 days) 
BASELINE 
PERIOD  
 (180 days) 
END OF ADHERENCE 
MEASUREMENT PERIOD 
 Figure C.1 Establishment of study cohort 
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Table C.1 Results of Cox proportional hazards models for individuals with major depressive disorder and anxiety – 
Exploring effect of 80% PDC threshold at one-year follow up 
  
MD Anxiety 
Censoring at one-year after end of adherence measurement period 
Models No cancer Cancer No cancer     Cancer 
Adherence (Ref= PDC <80%) 0.92 (0.84, 1.00) 1.01 (0.90, 1.13) 0.91 (0.81, 1.01) 0.90 (0.78, 1.05) 
Adherence + Demographic  0.93 (0.85, 1.01) 1.03 (0.92, 1.16) 0.91 (0.82, 1.02) 0.90 (0.77, 1.05) 
Adherence + Demographic + Enrollment 0.94 (0.86, 1.04) 1.03 (0.91, 1.16) 0.94 (0.84, 1.05) 0.90 (0.77, 1.05) 
Adherence + Demographic + Enrollment + 
Comorbid mental health and pain 
0.97 (0.88, 1.07) 1.06 (0.94, 1.20) 0.97 (0.87, 1.09) 0.93 (0.79, 1.08) 
Demographic covariates = Age in years, Gender, Race (White, Black or Other), Place of residence (Urban/Rural); Enrollment covariates= MCO/FFS, 
Eligibility categories (Disabled/Chronically Ill, Expansion, Families with Children, Others); Comorbid mental health conditions = alcohol and 
substance abuse disorders, adjustment disorders, other mental health conditions; Comorbid pain conditions = back pain, neck pain, arthritis/joint 
pain, headache/migraine; MDD = Major Depressive Disorder; PDC=Proportion of days covered; Bold refers to non-violation of proportional hazards 
assumption; * = p<0.05 
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Table C.2 Results of Cox proportional hazards models for individuals with major depressive disorder and anxiety – 
Exploring effect of multiple definitions of PDC and censoring at one-year after end of adherence measurement period 
  
MDD                      Anxiety  
No cancer Cancer No cancer Cancer 
Adherence variables only 
20% ≤ PDC <40% 0.76 (0.66, 0.88) * 0.92 (0.75, 1.12) 0.85 (0.71, 1.02) 0.87 (0.68, 1.11) 
40% ≤ PDC <60% 0.84 (0.72, 0.97) * 0.96 (0.78, 1.18) 0.77 (0.63, 0.94)* 0.87 (0.67, 1.13) 
60% ≤ PDC <80% 0.77 (0.66, 0.90) * 1.01 (0.82, 1.25) 0.84 (0.71, 1.05) 0.95 (0.73, 1.23) 
PDC ≥80%   0.76 (0.67, 0.87) ** 0.98 (0.82, 1.17) 0.78 (0.67, 0.92)* 0.83 (0.67, 1.02) 
PDC<20% Reference Reference Reference Reference 
Adherence + Demographic variables 
20% ≤ PDC <40% 0.78 (0.67, 0.90) * 0.91 (0.75, 1.11) 0.87 (0.73, 1.04) 0.87 (0.68, 1.11) 
40% ≤ PDC <60% 0.85 (0.73, 0.99) * 0.96 (0.78, 1.18) 0.79 (0.65, 0.96)* 0.87 (0.67, 1.13) 
60% ≤ PDC <80% 0.79 (0.67, 0.92) * 1.02 (0.83, 1.26) 0.88 (0.73, 1.07) 0.95 (0.73, 1.23) 
PDC ≥80%   0.77 (0.68, 0.89) * 1.00 (0.84, 1.20) 0.80 (0.68, 0.95)* 0.82 (0.66, 1.02) 
PDC<20% Reference Reference Reference Reference 
Adherence + Demographic + Enrollment variables 
20% ≤ PDC <40% 0.79 (0.69, 0.92) ** 0.92 (0.75, 1.12) 0.89 (0.74, 1.06) 0.87 (0.68, 1.11) 
40% ≤ PDC <60% 0.87 (0.75, 1.00)  0.96 (0.78, 1.18) 0.82 (0.67, 0.99)* 0.87 (0.67, 1.14) 
60% ≤ PDC <80% 0.81 (0.69, 0.94) * 1.03 (0.83, 1.27) 0.91 (0.75, 1.11) 0.95 (0.74, 1.24) 
PDC ≥80%   0.81 (0.71, 0.92) * 1.00 (0.84, 1.20) 0.84 (0.72, 0.99)* 0.83 (0.67, 1.03) 
PDC<20% Reference Reference Reference Reference 
Adherent + Demographic + Enrollment + Comorbid mental health and pain 
20% ≤ PDC <40% 0.86 (0.74, 0.99) * 0.93 (0.76,1.14) 0.99 (0.83, 1.19) 0.89 (0.69, 1.14) 
40% ≤ PDC <60% 0.90 (0.78, 1.05) 0.97 (0.79, 1.20) 0.84 (0.69, 1.02) 0.89 (0.68, 1.15) 
60% ≤ PDC <80% 0.91 (0.77, 1.06) 1.05 (0.85, 1.30) 0.99 (0.82, 1.23) 0.96 (0.74, 1.25) 
PDC ≥80%   0.88 (0.77, 1.01) 1.04 (0.87, 1.25) 0.93 (0.79, 1.10) 0.86 (0.69, 1.08) 
PDC<20% Reference Reference Reference Reference 
Demographic covariates = Age in years, Gender, Race (White, Black or Other), Place of residence (Urban/Rural); Enrollment covariates= MCO/FFS, 
Eligibility categories (Disabled/Chronically Ill, Expansion, Families with Children, Others); Comorbid mental health conditions = alcohol and substance 
abuse disorders, adjustment disorders, other mental health conditions; Comorbid pain conditions = back pain, neck pain, arthritis/joint pain, 
headache/migraine; MDD = Major Depressive Disorder; PDC=Proportion of days covered; Bold refers to non-violation of proportional hazards 
assumption; * = p<0.05 
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Table C.3 The International Classification of Diseases, Ninth Revision, Clinical Modification codes for major 
depressive disorders and anxiety 
 
Type of disorder ICD 9 codes 
Major Depressive Disorders 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32, 
296.33, 296.34, 296.35, 296.36, 300.4, 311, V79.0 
Anxiety Disorders 293.84, 300.00, 300.01, 300.02, 300.09, 300.10, 300.20, 300.21, 300.22, 300.23, 
300.29, 300.3, 300.5, 300.89, 300.9, 308.0, 308.1, 308.2, 308.3, 308.4, 308.9, 
309.81, 313.0, 313.1, 313.21, 313.22, 313.3, 313.82, 313.83  
Source: https://www.ccwdata.org/web/guest/condition-categories 
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Table C.4 The International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification codes for 
mental illness diagnoses that were excluded from the analysis 
 
Type of disorder ICD 9 ICD 10 
Alzheimer’s 331.0, 331.11, 331.19, 331.2, 331.7, 290.0, 290.10, 290.11, 290.12, 
290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 290.43, 294.0, 
294.10, 294.11, 294.20, 294.21, 294.8, 797 
F01.50, F01.51, F02.80, F02.81, F03.90, 
F03.91, F04, G13.2, G13.8, F05, F06.1, F06.8, 
G30.0, G30.1, G30.8, G30.9, G31.1, G31.2, 
G31.01, G31.09, G91.4, G94, R41.81, R54  
Schizophrenia and other 
psychotic disorders 
293.81, 293.82, 295.00, 295.01, 295.02, 295.03, 295.04, 295.05, 
295.10, 295.11, 295.12, 295.13, 295.14, 295.15, 295.20, 295.21, 
295.22, 295.23, 295.24, 295.25, 295.30, 295.31, 295.32, 295.33, 
295.34, 295.35, 295.40, 295.41, 295.42, 295.43, 295.44, 295.45, 
295.50, 295.51, 295.52, 295.53, 295.54, 295.55, 295.60, 295.61, 
295.62, 295.63, 295.64, 295.65, 295.70, 295.71, 295.72, 295.73, 
295.74, 295.75, 295.80, 295.81, 295.82, 295.83, 295.84, 295.85, 
295.90, 295.91, 295.92, 295.93, 295.94, 295.95, 297.0, 297.1, 297.2, 
297.3, 297.8, 297.9, 298.0, 298.1, 298.2, 298.3, 298.4, 298.8, 298.9  
F06.0, F06.2, F20.0, F20.1, F20.2, F20.3, 
F20.5, F20.81, F20.89, F20.9, F22, F23, F24, 
F25.0, F25.1, F25.8, F25.9, F28, F29, F32.3, 
F33.3, F44.89  
  
Bipolar 296.00, 296.01, 296.02, 296.03, 296.04, 296.05, 296.06, 296.10, 
296.11, 296.12, 296.13, 296.14, 296.15, 296.16, 296.40, 296.41, 
296.42, 296.43, 296.44, 296.45, 296.46, 296.50, 296.51, 296.52, 
296.53, 296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 
296.64, 296.65, 296.66, 296.7, 296.80, 296.81, 296.82, 296.89, 
296.90, 296.99  
F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, 
F30.4, F30.8, F30.9, F31.0, F31.10, F31.11, 
F31.12, F31.13, F31.2, F31.30, F31.31, 
F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, 
F31.63, F31.64, F31.70, F31.71, F31.72, 
F31.73, F31.74, F31.75, F31.76, F31.77, 
F31.78, F31.81, F31.89, F31.9, F32.8, F33.8, 
F34.8, F34.9, F39  
Dementia 292.82, 294.8   
Parkinsons 331.82 
  
G20.x 
Source: https://www.ccwdata.org/web/guest/condition-categories 
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Figure C.2 Sample-size flowchart for cohort with Major Depressive Disorders 
 
 
 
 
Total beneficiaries in the Pennsylvania Medicaid Program 
N= 5,626,740 
  
N=4,157,064 
N=14,670 
Exclude: 1) Non-Pennsylvania residents (n=213,021), then 
             2) Dual eligible (n=846,378), then 
                3) Alzheimer’s, Dementia, Bipolar, Schizophrenia, or     
                    Parkinson's (n=410,277) 
Exclude: 1) No anti-depressant (AD) use (n=3,728,817), then 
               2) Only one AD claim (n=81,910) 
  
Exclude: 1) No continuous enrollment 6 months before index date 
(n=57,380) 
               2) No continuous enrollment 6 months after index date 
(n=11,270) 
               3) Age <18 or age >64 years old (n=9,434)  
               4) Long-term care ≥90 days (n=227) 
               5) Receiving hospice benefits (n=34) 
                         
N=123,521 
N=346,337 
Exclude: 1) No depression diagnosis (n=120,973), then 
               2) No depression diagnosis within 30 days of first AD 
claim or prior to six months of first AD claim (n=101,843)  
  97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total beneficiaries in the Pennsylvania Medicaid Program 
N= 5,626,740 
  
N=4,157,064 
N=10,167 
Exclude: 1) Non-Pennsylvania residents (n=213,021), then 
             2) Dual eligible (n=846,378), then 
                3) Alzheimer’s, Dementia, Bipolar, Schizophrenia, or     
                    Parkinson's (n=410,277) 
Exclude: 1) No anti-depressant (AD) use (n=3,728,817), then 
               2) Only one AD claim (n=81,910) 
Exclude: 1) No continuous enrollment 6 months before index date (n=35,693) 
               2) No continuous enrollment 6 months after index date (n=9,762) 
               3) Age <18 or age >64 years old (n=9,104) , then 
               4) Long-term care ≥90 days (n=120) , then 
               5) Receiving hospice benefits (n=24) , then 
 6) Opioid use initiated before index AD use  and adherence 
measurement (n=2,1594)  
 7) Missing data (e.g. days –supply) in  pharmacy claims (n=60)  
N=86,524 
N=346,337 
Exclude: 1) No anxiety diagnosis (n=157,480), then 
               2) No anxiety diagnosis within 30 days of first AD claim or     
                   prior to six months of first AD claim (n=102,333) 
Figure C.3 Sample-size flowchart for cohort with Anxiety Disorders 
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Figure C.4 Distribution of the proportion of days covered for (A) Cohort with Major Depressive Disorders, and (B) Cohort with 
Anxiety Disorders 
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